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A brief summary of the work to be incorporated in the thesis entitled
“STUDIES ON COMPOUNDS OF MEDICINAL INTEREST’’  has
been  summar ized  as  under.
    ( A )   STUDIES ON  PYRIMIDINE  DERIVATIVES
    ( B )   STUDIES ON PYRIDO[2,3-d : 6,5-d’]DIPYRIMIDINES
    ( A )   STUDIES ON  PYRIMIDINE  DERIVATIVES
Pyrimidines  represents one of the most active classes of compounds
possessing a wide spectrum of biological activities viz. significant in vitro
activity  against  unrelated  DNA  and  RNA  viruses including  Polio  and  Herpes
viruses,  diuretics, antitubercular, antihypertensive  etc.  Some pyrimidines, which
occur as natural product like nucleic acids and vitamin-B and can be used as
therapeutic agent for the treatment of AIDS and antitumor. Keeping in
association of pyrimidines with varied activities, it was thought worthwhile to
synthesize some newer pyrimidines and its derivatives which can be summarized
as below.
PART - I :  STUDIES  ON  PYRIMIDINES
SECTION - I :  Preparation and biological evaluation of 2,4-Diamino-5-
               cyano-6-aryl-1,6-dihydro pyrimidines.
Pyrimidines (I) have been synthesized by the condensation of different








SECTION – II :  Preparation and biological evaluation of 2-Mercapto
       Methyl-4-amino-5-cyano-6-aryl-1,6-dihydro pyrimidines.
 2-Mercaptomethyl pyrimidines (II) have been synthesized by the
condensation of 2-mercapto-4-amino-5-cyano-6-aryl-1,6-dihydro pyrimidines with
dimethyl sulphate in  presence of the  base.
SECTION - III :  Preparat ion  and b io log ica l  eva luat ion  of  2 -Methy l
       sulphonyl-4-amino-5-cyano-6-aryl pyrimidines.
2-Methylsulphonyl-4-amino-5-cyano-6-aryl pyrimidines (III) have been
synthesized by the reaction of 2-mercaptomethyl-4-amino-5-cyano-6-aryl-1,6-
dihydro pyrimidines with hydrogen peroxide.
SECTION - IV :  Preparation and biological evaluation of 2-[(2’,4’-Dinitro
      pheny l ) th io ] -4 -amino-5 -cyano-6 -a ry l -1 ,6 -d ihydro
















(III) R = Aryl
3Synopsis
Pyrimidines (IV) have been synthesized by the condensation of
2-mercapto-4-amino-5-cyano-6-aryl-1,6-dihydro pyrimidines with 2,4-dinitro
chlorobenzene in presence of the base.
PART - II :  STUDIES ON  CARBOXAMIDO  PYRIMIDINES
The growing potent literature of recent years demonstrates that the
carboxamido pyrimidines are used as better cardiovascular, antihypertensive,
antitumor, anticonvulsant agents. Prompted by the above facts, some newer
carboxamido pyrimidines have been synthesized as under.
SECTION - I  :   Preparation and biological evaluation of 2,4-Diamino-
      5-carboxamido-6-aryl pyrimidines.
   2,4-Diamino-5-carboxamido-6-aryl pyrimidines (V) have been
synthesized by the reaction of 2,4-diamino-5-cyano-6-aryl-1,6-dihydro pyrimidines














(V) R = Aryl
4Synopsis
SECTION - II :  Preparation and biological evaluation of 2-Mercapto
    methyl-4-amino-5-carboxamido-6-aryl pyrimidines.
2-Mercaptomethyl-4-amino-5-carboxamido-6-aryl pyrimidines (VI) have
been synthesized by the reaction of 2-mercaptomethyl-4-amino-5-cyano-6-aryl-
1,6-dihydro pyrimidines with concentrated sulfuric acid at 0o C.
SECTION - III :  Preparation and biological evaluation of 2-Mercapto-4-
      amino-5-carboxamido-6-(2’-chloro substituted quinolin-3’
      -yl)-1,6-dihydro pyrimidines.
Pyrimidines (VII) have been synthesized by condensation of different
substituted 3-(2’-chloro quinolin-3’-yl)-2-cyanoacrylamides with thiourea.
SECTION - IV :  Preparation and biological evaluation of 2-Hydroxy-4-
      amino- 5-carboxamido-6-(2’-chloro substituted quinolin-3’






























Pyrimidines (VIII) have been synthesized by condensation of different
substituted 3-(2’-chloro quinolin-3’-yl)-2-cyanoacrylamides with urea.
SECTION - V :  Preparation and biological evaluation of 2,4- Diamino-
       5-carboxamido-6-(2’-chloro substituted quinolin-3’-
       yl)-1,6-dihydro pyrimidines.
Pyrimidines (IX) have been synthesized by condensation of different
substituted 3-(2’-chloro quinolin-3’-yl)-2-cyanoacrylamides with  guanidine
hydrochloride.
PART - III :  STUDIES ON PYRIMIDINYL SULPHONAMIDES
The study of sulphonamides has revealed valuable drugs for the disease
like cancer, tuberculosis, diabetics, malaria, leprosy and epilepsy. These valid
observations lead us to synthesize some novel sulphonamides, which have been
described as under.
SECTION - I :  Preparation and biological evaluation of 2-Mercapto-4-(p-
     acetamidophenyl sulphonylamino)-5-carboxamido-6-aryl
     pyrimidines.





















4-Pyrimidyl-sulphonamides (X) have been synthesized by the condensation of
2-mercapto-4-amino-5-carboxamido-6-aryl pyrimidines with p-acetamidophenyl sulphonyl
chloride in presence of pyridine.
SECTION - II :  Preparation and biological evaluation of 2-Mercapto-4-(p-amino
    phenyl sulphonylamino)-5-carboxamido-6-aryl pyrimidines.
2-Mercapto-4-(p-aminophenyl sulphonylamino)-5-carboxamido-6-aryl
pyrimidines (XI) have been synthesized by the hydrolysis of 2-mercapto-4-
(p-acetamidophenyl sulphonylamino)-5-carboxamido-6-aryl pyrimidines with
hydrochloric acid.
PART - IV :  STUDIES ON PYRAZOLO[3,4-d]PYRIMIDINES
Pyrazolo[3,4-d] pyrimidines are one of the most active class of compounds
possessing diverse biological activities viz. anticancer, antitumor, diuretic,
antipyretic and antimicrobial. Prompted by the above facts some new pyrazolo
[3,4-d]pyrimidines have been prepared as under.
SECTION - I :  Preparation and biological evaluation of 3-Amino-4-aryl-



















(XII) R = Aryl
7Synopsis
Pyrazolo[3,4-d]pyr imid ines (XI I )  have been synthesized by the
condensation of 2-mercaptomethyl-4-amino-5-cyano-6-aryl-1,6-dihydro
pyrimidines with hydrazine hydrate.
(B)     STUDIES ON PYRIDO[2,3-d : 6,5-d’]DIPYRIMIDINES
Pyrido[2,3-d : 6,5-d’]dipyrimidines represent one of the most active classes
of compounds possessing a wide spectrum of biological activit ies viz.
anticancer, antihypertensive, antitubercular. Keeping in association of pyrido
[2,3-d : 6,5-d’]dipyrimidines with varied activities, it was worthwhile to synthesize
some newer pyrido[2,3-d : 6,5-d’]dipyrimidines which can be summarized as
under.
SECTION - I :  Preparation and biological evaluation of 1,2,3,4,6,7,8,9-
     octahydro-10-aryl-5-(o-chlorophenyl)-2,4,6,8-tetraoxo-
     5H,10H-pyrido[2,3-d : 6,5-d’]dipyrimidines.
Pyrido[2,3-d : 6,5-d’]dipyrimidines (XIII) have been synthesized by the
condensation of 2-chlorobenzaldehyde with barbituric acid and  different
aromatic amines.
SECTION - II :  Preparation and biological evaluation of 1,2,3,4,6,7,8,9-
      octahydro-10-(p-methylphenyl)-5-aryl-2,8-dimercapto-












(XIII) R = Aryl
8Synopsis
Pyrido[2,3-d : 6,5-d’]dipyrimidines (XIV) have been synthesized by the
condensation of different aromatic aldehydes with thiobarbituric acid and
p-toluidine.
SECTION - III :  Preparation and biological evaluation of 1,2,3,4,6,7,8,9-
       octahydro-10-aryl-5-(m-nitrophenyl)-2,8-dimercapto-4,6-
       dioxo-5H,10H-pyrido[2,3-d : 6,5-d’]dipyrimidines.
Pyrido[2,3-d : 6,5-d’]dipyrimidines (XV) have been synthesized by the
condensation of 3-nitrobenzaldehyde with thiobarbituric acid and different
aromatic amines.
The constitutions of the products have been characterized by using

























(XV) R = Aryl
9Synopsis
The compounds have been screened for their in vitro therapeutic assay
like antibacterial activities towards S. pyogens MTCC-442 and S. aureus
MTCC-96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441
(Gram negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations (µg/ml) :
0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory  Concentration)






General Introduction 1 0
STUDIES ON COMPOUNDS OF MEDICINAL INTEREST
(A) Drug
The word drug is derived from the French word “drogue” which means a
dry herb. It is the single active chemical entity present in a medicine that is
used for diagnosis, prevention, treatment / cure of a disease. This disease
oriented definition of drug does not include contraceptives or use of drugs for
improvement of health. According to “WHO” a drug may be defined as “Any
substance or product which is used or intended to be used for modifying or
exploring physiological system as pathological status for the benefit of the
recipient”.
(B) Pharmacology
Pharmacology is the science of drugs. In a broad sense, it deals with
interaction of exogenously administered chemical molecules (drugs) with living
system. It encompasses all aspects of knowledge about drugs, but most
importantly those that are relevant to effective and safe use for medicinal
purposes. For thousands of years most drugs were crude natural products of
unknown composition and limited efficiency. Only the overt effects of these
substances on the body were rather imprecisely known, but how the same were
produced was entirely unknown. Over the past 100 years or so, drugs have been
purified, chemically characterized and a vast variety of highly potent and
select ive new drugs has been developed. The two main div is ions of
pharmacology are pharmacodynamics and pharmacokinetics.
(a) Pharmacodynamics : It is derived from the Greek word “dynamic” means
power. What the drugs does to the body ? This include physiological and
biochemical effects of drugs and their mechanism of action at macro
molecular / sub cellular organ system.
(b) Pharmacokinetics : It is derived from the Greek word Kinesis means
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movement. What the body does to the drug ? This refers to movements of
the drug in and alternation of the drug by the body; includes absorption,
distr ibut ion, binding /  local izat ion /  storage, biotransformation and
excretion of the drug.
Some other important aspects of pharmacology are given as under :
* Pharmacotherapecut ics  :  I t  i s  t he  app l i ca t i on  o f  pha rmaco-
dynamic information together with knowledge of the disease for its
prevention, mitigation or cure.
* Clinical  Pharmacology :  I t  is  the sc ient i f ic  s tudy of  drug in man.
I t  inc ludes pharmacodynamic and pharmacokinet ic  invest igat ion
in healthy volunteers and in patients; evaluation of efficiency and safety
o f  d rugs  and  compara t i ve  t r i a l s  w i th  o ther  fo rms  o f  t rea tments ;
surveillance of patterns of drug uses, adverse effects, etc.
* Chemotherapy : It is the treatment of systemic infection / malignancy
wi th  speci f ic  drugs that  have se lect ive tox ic i ty  for  the in fect ing
organism / malignant cell with less effect on the host cells.
Drugs in general, can thus be divided into :
* Pharmacodynamic agents : These are designed to have pharmaco-
dynamic effect in the recipient.
* Chemotherapeut ic  agents :  These are  des igned to  inh ib i t  /  k i l l
invading parasites / malignant cells and have no minimal pharmacodynamic
effects in the recipient.
(c) Essential Drug Concept: The WHO has defined Essential Drugs as “those
that satisfy the healthcare needs of majority of the population ; they should
therefore be available at all times in adequate amounts and in appropriate
dosage form”.
It has been realized that only a handful of drugs out of the multitude
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available can meet the health needs of majority of the people in any country, and
that may be well tested and cheaper drugs are equally (or more) efficient and
safe as their newer more expensive congeners. For optimum utilization of
resources, governments (specially in developing countries) should concentrate
on these drugs by identifying them as Essential Drugs. The “WHO” has laid down
criteria guide selection of an essential drug :
(I) Adequate data on its eff iciency and safety should be available from
          clinical studies.
(II) It should be available in a form in which quality, including bioavailability,
and stability on storage can be assured.
(III) Its choice should depend upon pattern of prevalent diseases; availability
o f  fac i l i t ies  and t ra ined personnel ;  f inanc ia l  resources;  genet ic ,
demographic and environmental factors.
(IV) In case of two or more similar drugs, choice should be made on the basis
          of their relative eff iciency, safety, quality, price, availabil i ty and cost
          benefit ratio should be a major consideration.
(V) Choice may also be influenced by comparative pharmacokinetic properties
and local facilities for manufacture and storage.
(VI) Most essential drug should be single compounds. Fixed ratio combination
products should be included only when dosage of each ingredient meets
the requirements of a defined population group, and when the combination
has a proven advantage.
(VII) Selection of essential drug should be a continuous process which should
take into account the changing priorities for public health action, epide-
miological condition as well as availability of better drugs/ formulations and
progress in pharmacological knowledge.
(C)  Drug Development
Many natural products by trial and error, came into practice for combating
human ailments existent during early human observation. With the advent of
modern scientific approach, various plant medicines came under chemical
scrutiny, ultimately leading to the isolation of active principles since early.
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Such compounds either in extracts form or in pure form became part of
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use
for over 5000 years for the treatment of various types of fever and respiratory
ailments, its active principle, Ephidrine was isolated in 1887. In 1925 chemical
investigations followed by pharmacological evaluation led this compound into the
modern medicine. Similarly during this period, urea stibamine was introduced as
the first drug in 1920 for the treatment of Kala-azar, in 1930. De Rauwolfia
preparation were first employed for sedative and hypotensive properties.
A drug is a substance having abnormal effect on certain body functions eg.
Strichinine stimulates the action of heart and aspirin still its action. Since both of
them effects abnormally, the two substances are known as drugs. Chemical
sciences contributed extensively new discoveries leading to useful drugs since
after 1930. The modern concept of drug discovery started in 1933 by Gerhand
Domagk with his finding of “Prontosil Red”, a compound responsible for the
antibacterial activity. The advent of sulphonamides drew the attention for the
different activity of various chemicals for bacterial and human cells, this
important factor prompted the Florey and Chain in 1939 to investigate penicillin
which was discovered ten years earlier by Alexander Fleming. The spectular
chemotherapeut ical  propert ies of penici l l in and i ts dramatic war-t ime
development for the treatment of wounds made penicillin, a most commonly used
inexpensive drug.
           A large number of important drugs have been introduced during the period
of 1940 to 1960. This period is known as “Golden period” of new drug discovery.
Thus starting from 1933 - the first antibacterial drug prontosil leading to various
sulpha drugs ; 1940 – penicillin ; 1945 – chloroquine – an antimalarial ; 1950 –
Methyldopa – antidiabetic; 1967 – chlorothiazine -diuretic; 1958 - adrenergic beta
b lockers  coronary  vasodi la tory ;  1960 -  semi  synthet ic  pen ic i l l in  -
antibacterial; 1965 -trimethoprim - antimicrobial; 1967 - disodium chromoglycoate
- antiallergic; 1972 - cimetidine H2 – antagonist; 1975 -verapamil - calcium
antagonist ‘1972 -; 1981 - captopril - antihypertensive; There are some specific
examples representing new therapeutics.
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(D) Latest Drug Developments
The current interest in the creation of large, searchable libraries of
organic compounds has captured the imagination of organic chemists and the
drug discovery community. Efforts in the numerous laboratories are focused on
the introduction of chemical diversity, which have been recently reviewed and
pharmacologically interesting compounds have been identified from libraries of
widely different compositions.
Today, the chief source of agents for the cure, the mitigation or the
prevention of diseases are organic compounds, natural or synthetic, together with
so-called organometallics. Such agents have their origin in a number of ways (a)
from naturally occurring materials - of both plant and animal origin, and (b) from
the isolation of organic compounds synthesized in laboratory whose structures
are closely related to those of naturally occurring compounds for eg. atropine,
steroids, morphine, cocaine etc. that have been showed to possess useful
medicinal properties.
The process of drug design is extensively driven by the instinct, intution
and experience of pharmaceutical research scientists. It is often instructive to
attempt to “capture” these experiences by analyzing the historical record that is
successful drug design projects of past. From this analysis the inferences drawn
to play an important role in shaping our on current and future projects. Towards
this region, we would like to analyse the structures of a large number of drugs -
the ultimate product of a successful drug design effort. Our goal for this is to  begin
to deconvolute, this information in order to apply it to design of new drugs.
Different kinds of drugs are developed for different types of diseases viz.
which can be defined with their names of the modern drugs as under.
(a) Anticancer drug
The drug, which stop the abnormal growth of cell tissues in human body,
are termed as anticancer drug. Vinblastin and Busulphan are the novel
anticancer drugs.
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(b) Hepatoprotective drugs
Drugs, which gives vitality to liver and protects liver by giving immunity power
against antibodies, are termed as Hepatoprotective drug.
(c) Antimalarial drugs
Drugs, which kills the plasmodium causing malaria are called antimalarial
drug. Combination of sulphamethoxazole with pyrimethamine is a novel
antimalarial drug.
(d)      Drug for meningitis
Drugs, which cures the inflammation of meningitis, are termed as
meningitis drugs - Cifalexin is a novel meningitis drug.
(e)      Drug for typhoid
Drug, which kills the bacteria of Salmonella typhi causing typhoid are known
as typhoid drugs. A novel drug for typhoid is ciprofloxacin.
(f)       Antidiabetic drug
Drug, which converts the excess glucose of blood into glycogen are termed
as antidiabetic drugs. Novel antidiabetic drugs are melformin, glipizide and
gliclazide.
(g) Antitubercular drugs
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus cures
lesions of pleural cavity. A novel antitubercular drug is ethambutol.
(h) Antiasthamatic drugs
             Drugs, which prevents the attack of asthama and gives relax respiration
are called antiasthamatic drugs. Novel antiasthamatic drugs are ethophylline,
theophylline and asmon.
(i) Antihypertensive drugs
            Drugs, which normalizes the blood pressure by dilating blood vessels are
called antihypertensive drugs. Novel antihypertensive drugs are atenolol,
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amlodopine and niphadipine.
(j)        Anti-AIDS drugs
          Drugs, which kills the viruses of AIDS i.e., HIV-1 and HIV-2 are called
anti-AIDS drugs. Novel drugs are zidovudine and didanosine.
(k) Antacid drugs
           Drugs, which neutralize the acid in stomach and stops excessive
secretion of acid, are called antacid drugs. Novel antacid drugs are omeprazole
and lansoprazole.
(l)       Non steroidal antiinflammatory drugs (NSAID)
Drugs, which gives relief from fever, pain and inflammation is called NSAID.
Novel NSAID are pyroxicam, meloxicam and nimesulide.
Different kind of drugs generally used as designed as anaesthetic,
ant i tubercu los ta t ic ,  ant ihyper tens ive,  ant iconvu lsant ,  anthe lmint ic ,
antiinflammatory, sedative and hypnotics which prompted us to synthesise drugs
having pyrimidine, quinoline, pyrazolo[3,4-d]pyrimidine, pyrido[2,3-d : 6,5-d’]
dipyrimidine moieties as a better therapeutic activity.
Aims and objectives of the present investigation are,
(ai) To generate several biologically active moieties such as pyrimidines,
            carboxamido pyrimidines,  pyrimidinyl sulphonamides, pyrazolo[3,4-d]
 pyrimidines, and pyrido[2,3-d : 6,5-d’]dipyrimidines.
(b) To characterize these products for their structural assignment using various
               spectroscopic techniques like IR, PMR and Mass spectroscopy.
(c) To screen these new derivatives for their antimicrobial activity using different
strains of bacteria and fungi and to compare antimicrobial activity with
different known drugs at different concentrations for their MIC values.
General Introduction 1 7
In view of these facts, the research work presented in thesis are as follows.
(A) Studies on pyrimidine derivatives
(B) Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
(A)
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Pyrimidine (1) is a six membered heterocyclic compound consisting of two
nitrogen atoms at 1 and 3 position of heterocyclic ring.
Generally pyrimidine derivatives such as 2-hydroxy pyrimidine, 2-mercapto
pyrimidine and 2-amino pyrimidine are studied. Pyrimidines have been isolated
from the nucleic acid hydrolysates.
Pyrimidines are among those molecules that make life possible, have
been some of the building blocks of DNA and RNA. Several analogs of
pyrimidines have been used as compounds that interfere with the synthesis and
functioning of nucleic acids e.g. fluorouracil, which has been used in cancer
treatment. Also there are some thiouracil derivatives, which produce adverse
reduction in susceptible patients and found more potent and less likely to
produce side effects and is being widely used1. There are several other
important groups of pyrimidines with medicinal uses.
Pyrimidine ring carrying various subtituents may be built up from two or
three aliphatic fragments by the principle synthesis or by a variety of other
synthesis, which are complimentary rather than alternative to it. A second type of
synthesis is the isomerisation or break down of another heterocycles such as an
hydration of purine but such roots are frequently used. Pyrimidine is best
considered as a resonance hybrid to which the uncharged equivalent Kekule




   pyrimidine
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consistent π (pi) electron densities required for the ground state of pyrimidine
are 0.776, 0.825 and 1.103 for positions 2, 4 and 5 respectively2. Despite
considerable localization of π (pi) electrons at nitrogen atoms of pyrimidines the
ring system is still sufficiently aromatic to possess substantial stability. This is
great advantage in the primary synthesis of pyrimidines.
The first primary synthesis from aliphatic fragments was carried out by
Frankland et al. in 1848. Since then a many distinct primary synthetic methods
have been devised3-12.  It is also possible to prepare pyrimidines from other
heterocyclic compounds such as pyrrole13, imidazole14, isoxazole and
oxazole15,16, pyridine17, pyrazine18, 1,3,5-triazine19, oxazine20, thiazine21 by
different processes.
SYNTHETIC ASPECTS
           Various methods for synthesis of pyrimidines  which are reported in the
literature are as follows.
(a) By the condensat ion of  urea and malonic  ac id led to  format ion of
pyr imidine22.
(b) By the condensat ion of  malonic ester and urea led to format ion of
pyr imidine23.
(c) By the condensat ion of  formamidine wi th phenylazomalononi t r i le
led to  format ion of  4,5,6-t r iamino pyr imidine24.
(d) B y  t h e  c o n d e n s a t i o n  o f  a r o m a t i c  a l d e h y d e s ,  ß - k e t o e s t e r  o r
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(e) By the condensation of thiourea and substituted ß-ketoester in presence
of sodiumethoxide led to formation of 2-mercapto pyrimidines26.
(f) By the condensation of chalcones with dicyandiamide in presence of
piperidine led to formation of pyrimidines27.
(g) By thermal or microwave irridiation of thiourea and substituted ß-ketoester
in presence of dimethylformamide led to formation of substituted tetra
hydro pyrimidines28.
Pyrimidines found their applications as herbicidal29, pesticidal30,31
agents. Yoshida et al.,32 have synthesized 4-amino-5-formyl-2-mercapto
pyrimidines as agrochemical intermediates. C. Srivastava et al.,33 have
synthesized new substituted pyrimidines (3) at C5- position of pyrimidine as
potential insecticides. N. Yasushi et al.,34 synthesized 6-(1-fluoro ethyl)-5-iodo-
4-alkylamino pyrimidines (4) as pesticides for agriculture and horticulture.
Besides such a great pharmacological importance of pyrimidines, they also
contribute to an important class of dye viz. trichloro pyrimidine35  dye which is a
reactive dye. Pyrimidines also have applications in liquid crystal composition36.
Many synthetic members of pyrimidines are important as vulcanizing accelerator
agents and  photography stabilizer37.
PHARMACOLOGICAL IMPORTANCE
Numerous pyrimidines are well known drugs for variety of diseases. They
may be placed in four categories viz. barbiturates, sulfonamides, antimicrobials














(3)            R = Alkyl/Aryl
(4)
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chroticacid, willardiline, tetradotoxine, becimethrian (5), blasticidine (6),
cougerotin, amicetin, bamicetin and plicacetin, phleomicine, blemycin and related
families (7).
Pyrimidine derivatives have wide varieties of usages. Pyrimidine ring
system is also present in Vitamin B2 and folic acid. Pyrimidine ring system
having a mercapto group occupy a unique position in medicinal chemistry38.
These types of derivatives play a vital role in biological processes39-41 as well
as synthetic drugs42.
The core of any rational drug discovery program is medicinal chemistry.
Although the synthesis of modified nucleic acids has been a subject of interest
for some time, the intense focus on the medicinal chemistry of oligonucleotides
dates perhaps to no more than four years. Consequently, the scope of
medicinal chemistry has recently expanded enormously, but the biological data
of support conclusions about synthetic strategies are only beginning to emerge.
Modi f ica t ions in  the base,  sugar  and phosphate moei t ies  o f
oligonucleotides have been reported. The subjects of medicinal chemical
programs include approaches to create enhanced affinity and more selective
affinity for RNA or duplex structures, the ability to cleave nucleic acid targets,
enhanced nuclease stability, cellular uptake and distribution and in vivo tissue
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Oligonucleotide  Medicinal  Chemistry  Program
Figure (8) shows the structure of an oligonucleotide, a number of design
features and various design strategies that have been implemented at other
laboratories. With regard to this class of molecules, as with all others. Increase
potency and selectivity by improving pharmacokinetic and pharmacodynamic
properties.
Although substantial progress in the medicinal chemistry oligonucleotides
has been made in the past three years, it is not yet possible to reach conclusions
about the therapeutic ability of the novel modifications. Preliminary data on
effects on nuclease stability and hybridization properties and for a few
modifications, activity in vitro suggest that the next generation of oligonucleotides
may display substantially improved potencies and selectivity.
PYRIMIDINE MODIFICATIONS
A selectivity large number of modified pyrimidines have been synthesized
and now evaluated in oligonucleotides. The principle sites of modification are






































"  Increased stability
"  Increased cellular uptake
"  Optimal hybridisation
"  Duplex recognition
"  Catalytic cleaving finction
"  Ease of synthesis
"  Patentability
ISIS Design Strategy
"  Exploit current oligo
     modifications
"  Functionality
     placement
"  Novel backbone
     modifications
"  Heterocycle
     modifications
"  Acid/base catalyzing
     functional groups
"  2’-substitution
"  α-oligonucleotides
"  Amphipathic group
(8)
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recently been thoroughly reviewed43. Consequently, a very brief summary of the
analogs that displayed interesting properties is incorporated here.
Sites of pyrimidine Modification
In as much as the C-5 position is involved in Watson-Crick hybridization,
C-2 modified pyrimidine containing oligonucleotides have shown unattractive
hybridization properties. An oligonucleotide containing 2-thiothymidine was found
to hybridize well to DNA and in fact, the Tm increased by approximately 0-5 °C
per modification44 .
In contrast , several modifications in the 4-position that have interesting
properties have been reported. 4-thio pyrimidines have been incorporated into
oligonucleotides with no significant negative effect on hybridization45. Finally, a
fluorescent base (10a) has been incorporated into oligonucleotides and shown
to enhance duplex stability46.
A large number of modifications at the C-5 position have also been
reported including halogenated nucleosides. (Although the stability of duplexes
may be enhanced by incorporating 5-halogenated nucleosides, the occasional
mispairing with G and the potential that the oligonucleotide might degrade may
cause the release of toxic nucleosides analogs43.
In general, as expected, modifications in the C-6 position of pyrimidines
are highly duplex destabi l iz ing47. Ol igonucleot ides containing 6-aza
pyrimidines (10b,10c) have been shown to reduce Tm by  1-2 = C per
modification, but to enhance the nuclease stability of oligonucleotides and to
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Pyrimidine Modifications
Some of the therapeutic activity of pyrimidine derivatives can be
summarized as follows.
(a) Antithyroid48
(b)      Antitumer49
(c)      Antihypertensive50-52
(d)      Antiinflammatory53,54
(e)      Diuretic55
(f)       Antimalarial56-58
(g)      Antispasmodic59
(h)      Anticonvulsant60
(i)       Antineoplastic61
(j)       Anthelmintic62
(k)      Antimicrobial63-88
(l)       Cardiovascular89-91
(m)     Antiviral92-94
(n)      Platelet aggregation inhibitor95,96
(o)      Antihistamine97
(p)      AntiHIV98
As a thyroid drug99 known as some thiouracil (11) derivatives have been
demonstrated recently. Propyl thiouracil is widely used probably because it has
fewer side effects than the others. Smith kline100 has synthesized (12) Cytosine
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N. Dhanapalan et al.,101 have been undertaken the preparation of (13) as
selective melanin concentrating hormone-1 (mch-1) receptor antagonists. W. Gerd
et al.,102 have synthesized pyridinyl pyrimidine (14) and tested for their ability to
inhibit the release of tumor necrosis factor-α (TNF-α) and interleukin-1β from
peripheral blood mononuclear cells (PBMC) and human whole blood. In the
pyrimidine series, structure activity relationship similar to those of the imidazole
series were found, although generally pyrimidine comps. were less potent
modification of the substituent at the 2-position of the pyrimidine led to the most
active comps.
W. Max et al.,103 have prepared (15) and their used in therapy of
IgE-synthesis-mediated diseases, autoimmune diseases, gastrointestinal
diseases and inflammatory diseases. M. K. Jani et al.,104 have synthesized
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Okada et al.,105 have synthesized pyrimidines (17) and their antitumor
activity were examined in vivo against P388 Leukemia. Some of the compounds















Safonova et al.,106 have synthesized pyrimidine derivatives (18) as
potent antitumor agents.
Recently, C. Jean-Damien et al.,107 have synthesized pyrazolyl pyrimidine
(19) as protein kinase inhibitors for treatment of cancer, diabetes and Alzheimer's














R4 = H/Alkyl R,R1 = Aryl
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K. Noriyuki et al.,109 have synthesized pyrimidine derivatives (21) as
antiHIV integrase inhibitory activity.
In view of procuring highly potent biodynamic agents and after reviewing
recent literature survey on 2-mercapto/amino pyrimidines for their various
methods of synthesis and different pharmacological activities, synthesis of
pyrimidines have been undertaken which can be summarized in the following





















SECTION - I :  PREPARATION AND BIOLOGICAL EVALUATION OF 2,4-
                          DIAMINO-5-CYANO-6-ARYL-1,6-DIHYDRO PYRIMIDINES.
SECTION - II : PREPARATION AND BIOLOGICAL EVALUATION OF 2-
                MERCAPTOMETHYL-4-AMINO-5-CYANO-6-ARYL-1 ,6 -
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SECTION - III : PREPARATION AND BIOLOGICAL EVALUATION OF 2-
         METHYLSULPHONYL-4-AMINO-5-CYANO-6-A RY L
                              PYRIMIDINES.
SECTION - IV :  PREPARATION AND B IOLOGICAL EVALUATION OF
                             2-[(2',4'-DINITROPHENYL)THIO]-4-AMINO-5-CYANO-6-
                            ARYL-1,6-DIHYDRO PYRIMIDINES.
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SECTION - I
PREPARATION AND EVALUATION OF 2,4-DIAMINO-5-CYANO-6-ARYL1,6-
DIHYDRO PYRIMIDINES
Due to other propert ies29-37 and biodynamic act iv i t ies48-104 of
pyrimidines and with a view to have potent therapeutic agents, the synthesis of
2,4-diamino-5-cyano-6-aryl-1,6-dihydro pyrimidines (Ia-j) have been undertaken
by the condensation of different aromatic aldehydes with malononitrile and
guanidine hydrochloride.
The constitution of the products (Ia-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (Ia-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds






Ia-j                 R=Aryl
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Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency



































 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
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   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (d ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3 ; Instrument : BRUKER Spectrometer
    (300 MHz)
 1.               3.918                              3H                           singlet                 -OCH3
 2.               7.001-7.030                   2H                           doublet               Ar-Ha,a’ (J=8.97)
 3.               7.654                              1H                           singlet                 Ar-Hc
 4.               7.899-7.929                   2H                           doublet               Ar-Hb,b’ (J=8.86)
 5.               9.157                              2H                           singlet                 -NH2




































































































































































































































































    (Ia-j)
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2,4-DIAMINO-5-CYANO-
6-ARYL-1,6-DIHYDRO PYRIMIDINES
(A) Preparation of 2,4-Diamino-5-cyano-6-(p-methoxyphenyl)-1,6-
dihydro pyrimidine (Ih).
A mixture of p-methoxybenzaldehyde (1.36 ml, 0.01 M), malononitrile
(0.66 ml, 0.01 M) and guanidine hydrochloride (0.96 gm, 0.01 M) in ethanol
(30 ml) was heated under refluxed condition for three hrs. Then the reaction
mixture was kept at room temperature for two hrs. The yellow crystalline
product  was obtained. The product was isolated and recrystallized from ethanol.
Yield : 48%, M.P. : 95°C, Rf : 0.68 (Required : C, 59.26%; H, 5.35%; N, 28.81%
for C12H13N5O, Found : C, 59.20%; H, 5.30%; N, 28.75%).
Similarly, other compounds (Ia-j) were synthesized. The physical data are
recorded in Table No. 1.
(B) Antimicrobial activity of 2,4-Diamino-5-cyano-6-aryl-1,6-dihydro
           pyrimidines (Ia-j).
Antimicrobial activity testing was carried out by using cup-plate method110,
which has been described as under.
     * Antibacterial activity
S. pyogens MTCC-442 and S. aureus MTCC-96 (Gram posit ive
bacteria) were grown in nutrient broth and E. coli MTCC-443 and B. subtillis
MTCC-441 (Gram negative bacteria) in Peptone water (PW, 1% bacteriological
peptone and 0.5% NaCl) for 24 hrs., this gave an optimum growth of the test
bacteria. Each purified compound was dissolved in DMF sterilized by filtration
by using sintered glass filter and stored at 4°C. Each agent was then added to
molten nutrient agar in the following concentrations (µg/ml) : 0 (control), 5, 10, 25,
3 6Studies on Pyrimidines
50, 100, 200, 500 and poured into sterile petri dished. The pH of the media was
maintained at 7.2 -7.4. The inoculum consisted of an overnight grown broth
culture of a bacterium diluted in such a manner that a 2 mm (internal diameter)
loopful of the culture contain 105 colony-forming unit (CFU). These were then spot
inoculated on nutrient  agar  plates containing increasing amount of a
compound, incubated at 37°C up to 24 hrs. for determination of the minimum
inhibitory concentration111,112 (MIC). Which are recorded in zones of inhibition
in mm for bacterias.
   * Antifungal activity
C. albicans MTCC-227 and A. niger MTCC-282 was employed for
testing antifungal activity using cup-plate method. The culture was maintained on
Sabouraud's agar for 72 hrs., this gave an optimum growth of the test fungal
spores. Each purified compound was dissolved in DMF sterilized by filtration by
using sintered glass filter and stored. Each agent was then added to Sabouraud's
agar in the following concentrations (µg/ml): 0 (control), 5, 10, 25, 50, 100, 200,
500 and poured into sterile petri dished. The inoculum consisted of an overnight
grown broth culture of a bacterium diluted in such a manner  than a 2 mm (internal
diameter) loopful of the culture contain 105 colony-forming unit (CFU). These were
then spot inoculated on Sabouraud's agar plates containing increasing amount
of a compound, incubated at 37°C up to 48 hrs. for determination of the minimum
inhibitory concentration (MIC)111,112. The MIC values of test solutions are
recorded in Table No. 1a, 1b & 1c .  Which are recorded in zones of inhibition in
mm for fungii.
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10 - - - - - - - - - -
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50 12 13 13 11 12 12 12 13 14 12
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SECTION - II
PREPARATION AND EVALUATION OF 2-MERCAPTOMETHYL-4-AMINO-5-
CYANO-6-ARYL-1,6-DIHYDRO PYRIMIDINES
Looking to other properties29-37  and biodynamic activities48-104 of
pyrimidines and with a view to have potent therapeutic agents, the synthesis of
2-mercaptomethyl-4-amino-5-cyano-6-aryl-1,6-dihydro pyrimidines (IIa-j) have
been undertaken by the condensation of 2-mercapto-4-amino-5-cyano-6-aryl-1,6-
dihydro pyrimidines with dimethyl sulphate in the presence of base.
The constitution of the products (IIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds






IIa-j                 R=Aryl
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Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.
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 skeletal vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
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4 3Studies on Pyrimidines
   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (d ppm)     of Proton
  Internal Standard : TMS ; Solvent ; CDCl3 ; Instrument : BRUKER Spectrometer
 (300 MHz)
 1.             2.368                        3H                       singlet             -SCH3
 2.             3.792                        3H                       singlet             -OCH3
 3.             6.914-6.943             2H                       doublet            Ar-Ha,a’(J=8.7)
 4.             7.791-7820              2H                       doublet            Ar-Hb,b’(J=8.7)
 5.                8.344                            1H                            singlet               Ar-Hc
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R = Aryl
REACTION SCHEME
    (IIa-j)
























4 7Studies on Pyrimidines
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTOMETHYL-
4-AMINO-5-CYANO-6-ARYL-1,6-DIHYDRO PYRIMIDINES
(A) Preparation of  2-Mercapto-4-amino-5-cyano-6-(p-methoxyphenyl)-
1,6-dihydro pyrimidine (1h).
A mixture of p-methoxybenzaldehyde (1.36 ml, 0.01 M), malononitrile
(0.66 ml, 0.01 M) and thiourea (0.76 gm, 0.01 M) in ethanol (30 ml) was heated
under refluxed condition for three hrs. Then the reaction mixture was kept  at  room
temperature for two hrs. The yellow crystall ine product was obtained. The
product was isolated and recrystallized from ethanol. Yield : 51%, M.P. : 120°C,
Rf : 0.62 (Required : C, 55.38%; H, 4.62%; N, 21.54% for C12H12N4OS, Found
: C, 55.32% ; H, 4.58%; N, 21.48%).
Similarly, other compounds (1a-j) were synthesized. The physical data are
recorded in Table No. 2.
(B) Preparation of 2-Mercaptomethyl-4-amino-5-cyano-6-(p-methoxy
phenyl)-1,6-dihydro pyrimidine (IIh).
A mixture of 2-mercapto-4-amino-5-cyano-6-(p-methoxyphenyl)-1,6-dihydro
pyrimidine (2.60 gm, 0.01 M) and dimethyl sulphate (1.26 ml, 0.01 M) in ethanol
(30 ml) and 40% aqueous sodium hydroxide was stirred for 12 hrs. at room
temperature. The content was poured into ice cold water and filtered. The
product was isolated and crystallized from ethanol. Yield : 62%, M.P. : 101°C;
Rf : 0.72, (Required : C, 56.93%; H, 5.11%; N, 20.44% for C13H14N4OS,
Found : C, 56.88%; H, 5.06%; N, 20.40%).
Similarly, other compounds (IIa-j) were synthesized. The physical data are
recorded in Table No. 3.
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(C) Antimicrobial activity of 2-Mercaptomethyl-4-amino-5-cyano-6-aryl-
1,6-dihydro pyrimidines (IIa-j)
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
3a, 3b & 3c.
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5 4Studies on Pyrimidines
SECTION - III
PREPARATION AND BIOLOGICAL EVALUATION OF 2-METHYL
SULPHONYL-4-AMINO-5-CYANO-6-ARYL PYRIMIDINES
In view of various biodynamic activities48-104 and other properties29-37
of  pyrimidines and in order to have highly potent therapeutic agents, the
synthesis of 2-methylsulphonyl-4-amino-5-cyano-6-aryl pyrimidines (IIIa-j) have
been undertaken by the reaction of 2-mercaptomethyl-4-amino-5-cyano-6-aryl-1,6-
dihydro pyrimidines with hydrogen peroxide.
The constitution of the products (IIIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IIIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds








IIIa-j                 R=Aryl
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Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.







































 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
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5 6Studies on Pyrimidines
    Internal Standard : TMS ; Solvent ; CDCl3 ; Instrument : BRUKER Spectrometer
    (300 MHz)
   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (d ppm)     of Proton
 1.               2.640                               3H                           singlet                -SO2CH3
 2.               7.498-7.561                   4H                           multiplet             Ar-Ha , Ar-Hb ,
                                                                                                                       Ar-Hc , Ar-Hd
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R = Aryl
REACTION SCHEME
    (1a-j)
    (IIa-j)
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-METHYL
SULPHONYL-4-AMINO-5-CYANO-6-ARYL PYRIMIDINES
(A) Preparation of 2-Mercaptomethyl-4-amino-5-cyano-6-(o-chloro
phenyl)-1,6-dihydro pyrimidine (IId).
For preparation refer Part-I, Section-II, Page No. 47.
(B) Preparation of 2-Methylsulphonyl-4-amino-5-cyano-6-(o-chloro
phenyl) pyrimidine (IIId).
2-mercaptomethyl-4-amino-5-cyano-6-(o-chlorophenyl)-1,6-dihydro
pyrimidine (2.785 gm, 0.01M) was dissolved in 20ml of glacial acetic acid and
add 12 ml of hydrogen peroxide and then kept for 48 hrs. at room temperature.
The content was poured into ice cold water and filtered. The product was isolated
and crystallized from ethanol. Yield : 56%, M.P. : 54°C, Rf : 0.63, (Required : C,
46.68%; H, 2.92%; N, 18.15% for C12H9N4O2SCl, Found : C, 46.62 %; H, 2.89%;
N, 18.12%).
Similarly, other compounds (IIIa-j) were synthesized. The physical data are
recorded in Table No. 4.
(C) Antimicrobial activity of 2-Methylsulphonyl-4-amino-5-cyano-6-aryl
pyrimidines (IIIa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
4a, 4b & 4c.
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PREPARATION AND BIOLOGICAL EVALUATION OF 2-[(2',4'-DINITRO
PHENYL)THIO]-4-AMINO-5-CYANO-6-ARYL-1,6-DIHYDRO PYRIMIDINES
Due to enormous biodynamic activities48-104 and other properties29-37
of  pyrimidines and with a view to have potent therapeutic agents, the synthesis
of 2-[(2',4'-dinitrophenyl)thio]-4-amino-5-cyano-6-aryl-1,6-dihydro pyrimidines
(IVa-j) have been undertaken by the condensation of 2-mercapto-4-amino-5-
cyano-6-aryl-1,6-dihydro pyrimidines with 2,4-dinitro chlorobenzene in presence
of the base.
The constitution of the products (IVa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IVa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
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Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.

















































 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)

































   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3 ; Instrument : BRUKER Spectrometer
    (300 MHz)
 1.                3.870                              3H                           singlet                  -OCH3
 2.                6.990-7.041                   4H                           multiplet               Ar-Ha,a’(J=8.5);
                                                                                                                          Ar-Hd (J=9.8);
                                                                                                                          Ar-Hc
 3.                7.208-7.238                   2H                           doublet                Ar-Hb,b’ (J=8.5)
 4.                8.114-8.155                   1H                           double doublet   Ar-He
 5.                9.156-9.166                   1H                           doublet                Ar-Hf
 6.                9.871                              1H                           singlet                  -N-H
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-[(2',4'-DINITRO
PHENYL)THIO]-4-AMINO-5-CYANO-6-ARYL-1,6-DIHYDRO PYRIMIDINES
(A) Preparation of 2-Mercapto-4-amino-5-cyano-6-(p-methoxyPhenyl)-
1,6-dihydro pyrimidine (1h).
For preparation refer Part-I, Section-II, Page No.47.
(B)     Preparation of 2-[(2',4'-Dinitrophenyl)thio]-4-amino-5-cyano-6-(p-
methoxyphenyl)-1,6-dihydro pyrimidine (IVh).
A mixture of 2-mercapto-4-amino-5-cyano-6-(p-methoxyphenyl)-1,6-dihydro
pyrimidine (2.60 gm, 0.01 M) and 2,4-dinitro chlorobenzene (2.02 gm, 0.01 M) in
ethanol (30 ml) and add 2 ml of 10% aqueous sodium hydroxide was heated
under refluxed condition for three hrs. The content was poured into ice cold water
and filtered. The product was isolated and crystallized from ethanol. Yield : 65%,
M.P. : 124°C, Rf : 0.64, (Required : C, 50.70%; H, 3.29%; N, 19.72% for
C18H14N6O5S, Found : C, 50.65%; H, 3.25%; N, 19.66%).
Similarly, other compounds (IVa-j) were synthesized. The physical data are
recorded in Table No. 5.
(C) Antimicrobial activity of 2-[(2',4'-Dinitrophenyl)thio]-4-amino-5-
cyano-6-aryl-1,6-dihydro pyrimidines (IVa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
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PART - II
STUDIES ON CARBOXAMIDO PYRIMIDINES
INTRODUCTION
Carboxamides are the substituted product of ammonia and acid. The
characteristic group present in the simple carboxylic amide is -CONH2. Many
natural products are amides, urea, diamides of carbonic acid. Peptides and
proteins are the linear structures of cyclic polyamides. Alkaloids of pepper,
piperine and chavicine are N-substituted amides of unsaturated acid. N-isobutyl
amides of certain highly unsaturated aliphatic acids occur in plants and show
insecticidal activity113. Amides derived from polyacetylenic acids have been
isolated from certain fungi114. Herbicidal and insecticidal activities115,116 are
well documented in literature.
SYNTHETIC ASPECTS
Several methods for the preparation of Carboxamides have been
described as under :
(a) By the reaction of 2-amino-4,6-dimehtyl pyrimidine and 2,5-dimethyl
pyrrole with CISO2CNO led to the formation of carboxamido pyrimidine117.
(b) By the acylation of the amino acid with p-chlorobenzoylchloride, then
converting the acid into the cyclohexylamide via  lactam, lactone or
anhydride to yield 2,4-dihydroxy-5-(p-chlorobenzamido)-6-cyclohexyl
aminocarbonyl) pyrimidine118.
(c) By the cyclization of 2-cyano-3-aryl acrylamide with thiourea led to the
formation of carboxamido pyrimidines119.
(d) By the condensation of 2-thiobarbituric acid with phenyl isocyanate led to
the formation of carboxamido pyrimidines120.
(e) By the reaction of 2-trifluoro methyl-5-methylsulphonyl-1,3,4-triazole and
4-hydroxyaniline with hexahydro-2,4,6-trioxo-5-pyrimidine carboxylate
led to the formation of carboxamido pyrimidines121.
Studies on carboxamido pyrimidines 82
(f) By the cyclocondensation of 1,2-dibromo-1-carboxyl-2-ethanal with
chlorinated product aminated by p-f luoroanil ine which on further
oxidation led to the formation of carboxamido pyrimidines122.
THERAPEUTIC IMPORTANCE
Carboxamide pyrimidines have been widely used as pharmacologically




















H.E. Weidermann et al.,152 have synthesized pyrimidine carboxamides
(22) which reduces blood sugar in rats by 19% at 5mg/kg.
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U. Herzog et al.,153 have synthesized pyrimidine carboxamides (23) as
promising amoebicides and protozoacides.
P.F. Juby et al.,154 have prepared pyrimidine-5(N)-(1H-tetrazol-5-yl)
carboxamides (24) which showed antiallergic activity.
K.  Atwal et al.,155 have synthesized 5-pyrimidine carboxylic acids (25)








R1=H/napthyl/alkyl;        R2,R3=H/alkyl;












(22) R=sub sulphonamido piperidyl
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B. Ojo et al.,156 have synthesized 1,4,5,6-tetrahydro pyrimidine
5-carboxamides (26, 27) and their salts, having binding affinities and agonist
activity at muscarinic receptor in the CNS.
H. Hisamichi et al.,157 have synthesized pyrimidine-5-carboxamido
derivatives (28) as effective tyrosinase inhibitor useful as 5-HT antagonist and
antiallergic.
F. Kobayashi et al.,158 have prepared (1,6-dihydro-6-oxo-1-pyrimidinyl-1-
pyridinyl) acetamide derivatives (29) as antibody production inhibitors are useful



























X=O/S/NR1/CO/CONR1; Y=lower alkylene-optionally subs. by OR or 
NHR1; Z=O, NR2, A=H, B=Optically subs. aryl / heteroaryl; R1,R2= H 
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U. Pfaar et al.,159 have prepared carboxamido pyrimidine derivatives (30)
and reported for their antitumor activity.
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on carboxamide pyrimidine for their various methods of
synthesis and different biological activities, synthesis of carboxamide pyrimidines
have been undertaken which can be summarized in the following sections as
under.
    R1=OH;  R2=H/alkyl/hydroxyalkyl;  A=NR3R4/CR3R4/OR3R4;



















Studies on carboxamido pyrimidines 86
SECTION – I :  PREPARATION AND BIOLOGICAL EVALUATION OF  2,4-
                          DIAMINO-5-CARBOXAMIDO-6-ARYL PYRIMIDINES
 SECTION – II :  PREPARATION AND BIOLOGICAL EVALUATION OF
                            2-MERCAPTOMETHYL-4-AMINO-5-CARBOXAMIDO-6-
                            ARYL PYRIMIDINES
SECTION – III : PREPARATION AND BIOLOGICAL EVALUATION OF 2-
                           MERCAPTO-4-AMINO-5-CARBOXAMIDO-6-(2’-CHLORO
                           SUBSTITUTED QUINOLIN-3’-YL)-1,6-DIHYDRO PYRIMIDINES
SECTION - IV :  PREPARATION AND BIOLOGICAL EVALUATION OF 2-
                            HYDROXY-4-AMINO-5-CARBOXAMIDO-6-(2'-CHLORO
                            SUBSTITUTED QUINOLIN-3'-YL)-1,6-DIHYDRO PYRIMIDINES
SECTION - V :   PREPARATION AND BIOLOGICAL EVALUATION OF 2,4-
                            DIAMINO-5-CARBOXAMIDO-6-(2'-CHLORO SUBSTITUTED
                            QUINOLIN-3'-YL)-1,6-DIHYDRO PYRIMIDINES
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 2,4-DIAMINO-5-
CARBOXAMIDO-6-ARYL PYRIMIDINES
Looking to the biodynamic profile123-159 and the other properties113-116
of carboxamido pyrimidines and in view to have potent therapeutic agents, the
synthesis of 2,4-diamino-5-carboxamido-6-aryl pyrimidines (Va-j) have been
undertaken by the reaction of 2,4-diamino-5-cyano-6-aryl-1,6-dihydro pyrimidines
with concentrated sulphuric acid.
The constitution of the products (Va-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (Va-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds






Va-j                 R=Aryl
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Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.
          Observed       Reported
 IR SPECTRAL STUDY OF 2,4-DIAMINO-5-CARBOXAMIDO-6-(p-METHOXY


























 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
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   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3 ; Instrument : BRUKER Spectrometer
    (300 MHz)
 1.        3.919            3H        singlet            -OCH3
 2.        7.002-7.032            2H                    doublet            Ar-Ha,a’ (J=8.86)
 3.        7.900-7.930            2H        doublet               Ar-Hb,b’ (J=8.93)
 PMR SPECTRAL STUDY OF 2,4-DIAMINO-5-CARBOXAMIDO-6-(p-METHOXY
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2,4-DIAMINO-5-
CARBOXAMIDO-6-ARYL PYRIMIDINES
(A) Preparation of 2,4-Diamino-5-cyano-6-(p-methoxyphenyl)-1,6-
          dihydro pyrimidine (Ih).
For preparation refer Part-I, Section-I, Page No. 35.
(B) Preparation of 2,4-Diamino-5-carboxamido-6-(p-methoxyphenyl)
          pyrimidine (Vh).
2,4-Diamino-5-cyano-6-(p-methoxyphenyl)-1,6-dihydro pyrimidine (2.43 gm,
0.01M) was dissolved in concentrated sulphuric acid (20ml) below 5 oC and kept
for 48 hrs. at room temperature. The content was poured into ice cold water and
filtered. The product was isolated and crystallized from ethanol. Yield : 53%, M.P.
: 147°C, Rf : 0.58, (Required : C, 55.60%; H, 5.02%; N, 27.03% for C12H13N5O2,
Found : C, 55.55%; H, 4.98%; N, 27.00%).
Similarly, other compounds (Va-j) were synthesized. The physical data are
recorded in Table No. 6.
(C) Ant imicrobia l  ac t iv i ty  o f  2 ,4 -Diamino-5 -carboxamido-6 -ary l
          pyrimidines (Va-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
6a, 6b & 6c.
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5 - - - - - - - - - -
10 - - - - - - - - - -
25 10 10 12 11 12 10 10 12 11 11
50 10 11 12 11 12 10 11 12 11 11
10
0
12 13 14 13 14 12 12 13 13 12
25
0
14 14 14 13 14 14 13 14 14 14
50
0
14 14 15 14 15 15 13 14 14 14
5 - - - - - - - - - -
10 - - - - - - - - - -
25 12 11 14 12 14 11 11 14 12 13
50 12 13 15 12 14 12 12 14 13 13
10
0
14 15 16 14 15 14 14 15 15 14
25
0
15 16 17 15 16 14 14 16 15 16
50
0







































































































































































11 10 16 18
14 13 19 19
16 19 21 20
18 20 21 21
19 20 22 21
20 22 22 23
10 12 17 19
13 14 19 22
14 19 21 25
16 20 22 26
18 21 22 28
21 22 23 28



































































   
   
   
   
   
   
   
   
   
















































































   
   
   
   

























































   
   
   
   
   









   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   











5 - - - - - - - - - -
10 - - - - - - - - - -
25 13 12 15 14 15 13 13 15 14 14
50 14 13 16 15 16 13 14 16 14 15
10
0
15 14 17 16 17 15 15 17 16 16
25
0
17 16 17 17 17 16 16 18 17 17
50
0
17 17 18 17 18 18 16 18 18 18
5 - - - - - - - - - -
10 - - - - - - - - - -
25 15 14 15 16 15 15 14 17 14 16
50 16 15 15 17 17 15 16 17 16 16
10
0
17 17 16 17 17 17 18 18 18 17
25
0
18 18 18 18 18 18 17 19 18 19
50
0







































































































































































14 14 20 22
15 17 23 25
16 23 28 26
19 23 28 27
20 23 28 29
22 23 28 29
12 12 16 19
18 16 19 22
19 19 22 23
20 22 22 24
21 23 23 25
23 23 23 28
















































































   
   
   
   
   
   
   
   
   


































































   
   
   
   

























































   
   
   
   
   












   
   
   
   
   
   
   
   
   
   
   
   
   
   
   










5 - - - - - - - - - -
10 - - - - - - - - - -
25 17 16 17 17 17 17 17 17 17 17
50 18 17 18 17 17 18 18 18 17 18
10
0
19 18 19 19 19 18 19 20 19 19
25
0
20 19 20 19 20 19 20 21 20 19
50
0
22 20 21 20 20 20 20 22 21 20
5 - - - - - - - - - -
10 - - - - - - - - - -
25 18 18 18 18 18 18 19 19 18 19
50 19 19 19 19 19 19 19 19 19 19
10
0
20 20 20 21 20 20 21 21 21 20
25
0
21 21 20 22 21 21 21 23 21 22
50
0
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO
METHYL-4-AMINO-5-CARBOXAMIDO-6-ARYL PYRIMIDINES
Looking to the biodynamic profile123-159 and the other properties113-116
of carboxamido pyrimidines and with a view to have potent therapeutic agents,
the synthesis of 2-mercaptomethyl-4-amino-5-carboxamido-6-aryl pyrimidines
(VIa-j) have been undertaken by the reaction of 2-mercaptomethyl-4-amino-5-
cyano-6-aryl-1,6-dihydro pyrimidines with concentrated sulphuric acid.
The constitution of the products (VIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (VIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds







VIa-j                 R=Aryl
Studies on carboxamido pyrimidines 99
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.
          Observed       Reported
 IR SPECTRAL STUDY OF 2 - M E R C A P T O M E T H Y L - 4 - A M I N O - 5 -



































 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
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   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3+DMSOd6 ; Instrument : BRUKER
    Spectrometer (300 MHz)
 1.        2.653            3H        singlet            S-CH3
 2.               3.897            3H        singlet                 -OCH3
 3.               7.012-7.042            2H                    doublet            Ar-Ha,a’ (J=8.83)
 4.        8.082-8.112                   2H        doublet            Ar-Hb,b’ (J=8.86)
 PMR SPECTRAL STUDY OF 2 - M E R C A P T O M E T H Y L - 4 - A M I N O - 5 -
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTOMETHYL-
4-AMINO-5-CARBOXAMIDO-6-ARYL PYRIMIDINES
(A) Preparation of 2-Mercaptomethyl-4-amino-5-cyano-6-(p-methoxy
           phenyl)-1,6-dihidro pyrimidine (IIh).
         For preparation refer Part-I, Section-II, Page No. 47.
(B) Preparation of 2-Mercaptomethyl-4-amino-5-carboxamido-6-
          (p-methoxyphenyl) pyrimidine (VIh).
2-Mercaptomethyl-4-amino-5-cyano-6-(p-methoxyphenyl)-1,6-dihydro
pyrimidine (2.74 gm, 0.01M) was dissolved in concentrated sulphuric acid (20ml)
below 5 oC and kept for 48 hrs. at room temperature. The content was poured in
to ice cold water and filtered. The product was isolated and crystallized from
ethanol. Yield : 56%, M.P. : 185°C, Rf : 0.61, (Required : C, 53.79%; H, 4.83%; N,
19.31% for C13H14N4O2S, Found : C, 53.73%; H, 4.80%; N, 19.25%).
.
          Similarly, other compounds (VIa-j) were synthesized. The physical data are
recorded in Table No. 7.
(C) Antimicrobial activity of 2-Mercaptomethyl-4-amino-5-carboxamido
          -6-aryl pyrimidines (VIa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
7a, 7b & 7c.
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5 - - - - - - - - - -
10 - - - - - - - - - -
25 10 11 10 12 11 12 10 10 11 12
50 10 11 10 12 11 12 10 11 11 12
10
0
12 13 12 14 12 14 12 13 12 14
25
0
13 14 12 14 13 14 12 13 14 14
50
0
14 14 14 14 13 14 14 14 14 14
5 - - - - - - - - - -
10 - - - - - - - - - -
25 11 13 12 14 12 14 12 11 12 13
50 12 14 12 14 13 14 13 12 13 14
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SECTION - III
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-
AMINO-5-CARBOXAMIDO-6-(2'-CHLORO SUBSTITUTED QUINOLIN-3'-YL)-
1,6-DIHYDRO PYRIMIDINES
Due to wide range of biological activities123-159, recent literature
survey117-122, other properties113-116 and in view to have potent therapeutic
agents, the synthesis of 2-mercapto-4-amino-5-carboxamido-6-(2'-chloro
substituted quinolin-3'-yl)-1,6-dihydro pyrimidines (VIIa-j) have been undertaken
by the reaction of 3-(2'-chloro substituted quinolin-3'-yl)-2-cyanoacrylamides  with
thiourea.
The constitution of the products (VIIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (VIIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
were compared with standard drugs.
VIIa-j                R=2-Chloro
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Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.
          Observed       Reported
 IR SPECTRAL STUDY OF 2-MERCAPTO-4-AMINO-5-CARBOXAMIDO-6-









































 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
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   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3+DMSOd6 ; Instrument : BRUKER
    Spectrometer (300 MHz)
 1.        3.948            3H        singlet           -OCH3
 2.               7.336-7.375            1H                           double doublet  Ar-Hb
 3.               7.722            4H                           multiplet             Ar-He+ NH2+ NH
 4.        7.853-7.883            1H        doublet            Ar-Hc (J=9.02)
 5.        8.127-8.135            1H        doublet               Ar-Ha (J=2.41)
 6.        8.631                              1H        singlet                Ar-Hd
 PMR SPECTRAL STUDY OF 2-MERCAPTO-4-AMINO-5-CARBOXAMIDO-6-
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REACTION SCHAME
R = 2-Chloro substituted
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-
AMINO-5-CARBOXAMIDO-6-(2'-CHLORO SUBSTITUTED QUINOLIN-3'-YL)-
1,6-DIHYDRO PYRIMIDINES
(A) Preparation of 3-(2'-chloro-6'-methoxy quinolin-3'-yl)-2-cyano
          acrylamide (2f).
To the mixture of 2-chloro-6-methoxy quinolin-3-carboxaldehyde (2.22 gm,
0.01 M) and cyano acetamide (0.84 gm, 0.01 M) in DMF(30 ml), 8 ml of glacial
acetic acid was added and the reaction mixture was stirred for 48 hrs. at room
temperature . The  content was poured into ice cold water and filtered. The
product was isolated and crystallized from ethanol. Yield : 68%, M.P. : 127°C,
Rf : 0.62, (Required : C, 58.43%; H, 3.48%; N, 14.61% for C14H10N3O2Cl,
Found : C, 58.39%; H, 3.43%; N,  14.56%).
Similarly, other compounds (2a-k) were synthesized. The physical data
are recorded in Table No. 8.
(B) Preparation of 2-Mercapto-4-amino-5-carboxamido-6-(2'-chloro-
          6'-methoxy quinolin-3'-yl)-1,6-dihydro pyrimidine (VIIf).
           A mixture of 3-(2'-chloro-6'-methoxy quinolin-3'-yl)-2-cyano acrylamide
(2.88 gm, 0.01M) and thiourea (0.76 gm, 0.01M) in DMF (20 ml) was heated in
an oil-bath at 130 oC for 8 hrs. in presence of potassium carbonate. The
content was poured into ice cold water and neutralized with diluted hydrochloric
acid and filtered. The product was isolated and crystallized from DMF. Yield :
62%, M.P. : 116°C, Rf : 0.59, (Required : C, 49.52%; H, 3.85%; N, 19.26 % for
C15H14N5O2SCl; Found : C, 49.50%; H, 3.81%; N, 19.21%).
Similarly, other compounds (VIIa-j) were synthesized. The physical data are
recorded in Table No. 9.
Studies on carboxamido pyrimidines 116
(C)     Antimicrobial activity of 2-Mercapto-4-amino-5-carboxamido-6-
          (2'-chloro substituted quinolin-3'-yl)-1,6-dihydro pyrimidines (VIIa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
9a, 9b & 9c.
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SECTION - IV
PREPARATION AND BIOLOGICAL EVALUATION OF 2-HYDROXY- 4-AMINO-
5-CARBOXAMIDO-6-(2'-CHLORO SUBSTITUTED QUINOLIN-3'-YL)-1,6-
DIHYDRO PYRIMIDINES
Due to wide range of biological activities123-159, recent literature
survey117-122, other properties113-116 and in view to have potent therapeutic
agents, the synthesis of 2-hudroxy-4-amino-5-carboxamido-6-(2'-chloro
substituted quinolin-3'-yl)-1,6-dihydro pyrimidines (VIIIa-j) have been undertaken
by the reaction of 3-(2'-chloro substituted quinolin-3'-yl)-2- cyanoacrylamides  with
urea.
The constitution of the products (VIIIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (VIIIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds






VIIIa-j           R=2-Chloro
                substituted  Quinolin-3-yl
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Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.
          Observed       Reported
  IR SPECTRAL STUDY OF 2-HYDROXY-4-AMINO-5-CARBOXAMIDO-6-(2'-















































































 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
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   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3+TFA ; Instrument : BRUKER Spectrometer
    (300 MHz)
 1.               2.652                              3H        singlet            -CH3
 2.               7.881            2H                           singlet                 -NH2
 3.               7.930-7.944                  1H                            doublet               Ar-Ha
 4.               7.986-8.017                  1H                            doublet               Ar-Hc
 5.               8.106                             1H                            singlet                 -NH
 6.               8.162-8.190                  1H                            double doublet  Ar-Hb
 7.               8.828                             1H                            singlet                 Ar-He
 8.               9.181                             1H                            singlet                 Ar-Hd
 9.               10.511                           1H                            singlet                 -OH
 PMR SPECTRAL STUDY OF 2-HYDROXY-4-AMINO-5-CARBOXAMIDO-6-(2'-
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REACTION SCHAME
R = 2-Chloro substituted
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-HYDROXY-4-AMINO-
5-CARBOXAMIDO-6-(2'-CHLORO SUBSTITUTED QUINOLIN-3'-YL)-1,6-
DIHYDRO PYRIMIDINES
(A) Preparat ion of  3- (2 ' -chloro-6 ' -methyl  quinol in-3 ' -y l ) -2-cyano
          acrylamide (2d).
For preparation refer Part-II, Section-III, Page No. 115.
(B) Preparation of 2-Hydroxy-4-amino-5-carboxamido-6-(2'- chloro-6'-
           methyl quinolin-3'-yl)-1,6-dihydro pyrimidine (VIIId).
A mixture of 3-(2'-chloro-6'-methyl quinolin-3'-yl)-2-cyano acrylamide
(2.72 gm, 0.01M) and urea (0.60 gm, 0.01 M) in DMF (20 ml) was heated in an
oil-bath at 130 oC for 8 hrs. in presence of potassium carbonate. The content
was poured into ice cold water and neutralized with diluted hydrochloric acid and
filtered. The product was isolated and crystallized from DMF. Yield : 61%, M.P. :
178°C, Rf : 0.49, (Required : C, 54.30%; H, 4.22%; N, 21.12% for C15H14N5O2Cl;
Found : C, 54.25%; H, 4.18%; N, 21.08%).
Similarly, other compounds (VIIIa-j) were synthesized. The physical data
are recorded in Table No. 10.
(C) Antimicrobial activity of 2-Hydroxy-4-amino-5-carboxamido-6-
          (2'-chloro substituted quinolin-3'-yl)-1,6-dihydro pyrimidines (VIIIa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
10a, 10b & 10c.
Studies on carboxamido pyrimidines 129
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SECTION -V
PREPARATION AND BIOLOGICAL EVALUATION OF 2,4-DIAMINO-5-
CARBOXAMIDO-6-(2'-CHLORO SUBSTITUTED QUINOLIN-3'-YL)-1,6-
DIHYDRO PYRIMIDINES
Due to wide range of biological activities123-159, recent literature
survey117-122, other properties113-116 and in view to have potent therapeutic
agents, the synthesis of 2,4-diamino-5-carboxamido-6-(2'-chloro substituted
quinolin-3'-yl)-1,6-dihydro pyrimidines (IXa-j) have been undertaken by the
reaction of 3-(2'-chloro substituted quinolin-3'-yl)-2-cyanoacrylamides with
guanidine hydrochloride.
The constitution of the products (IXa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IXa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds






    IXa-j              R=2-Chloro
                   substituted  Quinolin-3-yl
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Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.
          Observed       Reported
 IR SPECTRAL STUDY OF 2,4-DIAMINO-5-CARBOXAMIDO-6-(2'-CHLORO





































 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
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   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3 ; Instrument : BRUKER Spectrometer
    (300 MHz)
 1.               3.951            3H       singlet            -OCH3
 2.               7.081                              2H                   singlet                  -NH2
 3.               7.106-7.115                   1H                          doublet                Ar-Ha (J=2.379)
 4.               7.420-7.460                  1H                           double doublet   Ar-Hb
 5.               7.917-7.948                  1H                           doublet                Ar-Hc (J=9.2)
 6.               8.404                             1H                           singlet            Ar-He
 7.        8.920                             1H                           singlet            Ar-Hd
 PMR SPECTRAL STUDY OF 2,4-DIAMINO-5-CARBOXAMIDO-6-(2'-CHLORO
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REACTION SCHAME
R = 2-Chloro substituted
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2,4-DIAMINO-5-
CARBOXAMIDO-6-(2'-CHLORO SUBSTITUTED QUINOLIN-3'-YL)-1,6-
DIHYDRO PYRIMIDINES
(A) Preparation of 3-(2'-chloro-6'-methoxy quinolin-3'-yl)-2-cyano
          acrylamide (2f).
          For preparation refer Part-II, Section-III, Page No. 115.
(B) Preparation of 2,4-Diamino-5-carboxamido-6-(2'-chloro-6'-methoxy
quinolin-3'-yl)-1,6-dihydro pyrimidine (IXf).
A mixture of 3-(2'-chloro-6'-methoxy quinolin-3'-yl)-2-cyano acrylamide
(2.88 gm, 0.01M) and guanidine hydrochloride (0.96 gm, 0.01) in DMF (20 ml)
was heated in an oil-bath at 130 oC for 8 hrs. in presence of potassium
carbonate. The content was poured into ice cold water and neutralized with
diluted hydrochloric acid and filtered. The product was isolated and crystallized
from DMF. Yield : 64%, M.P. : 108°C, Rf : 0.59, (Required : C, 51.95%; H, 4.33%;
N, 24.24% for C15H15N6O2Cl; Found : C, 51.90%; H, 4.30%; N, 24.19%).
Similarly, other compounds (IXa-j) were synthesized. The physical data are
recorded in Table No. 11.
(C) Antimicrobial activity of 2,4-Diamino-5-carboxamido-6-(2'- chloro
          substituted quinolin-3'-yl)-1,6-dihydro pyrimidines (IXa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
11a, 11b & 11c.
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5 - - - - - - - - - -
10 - - - - - - - - - -
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10
0
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0
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19 20 22 21
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10 12 17 19
13 14 19 22
14 19 21 25
16 20 22 26
18 21 22 28
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PART - III
STUDIES ON PYRIMIDINYL SULPHONAMIDES
INTODUCTION
The d iscovery  o f  su lphonamides marked the beg inn ing o f
chemotherapeutic era by making possible, a direct attack on microbial
infections 160. Sulphonamide antibacterial continued to be used because they
are effective, inexpensive and free of super infection problems of the broad
spectrum antibiotics161.
General formula of sulphonamides - R-SO2-N-R'-R"
R=Organic radicals, R'and R"= hydrogen or organic radical.
Depending upon the nature of R, the sulphonamides are classified as
aliphatic, aromatic and heterocyclic. The aliphatic sulphonamides have not yet
become important. Aromatic and heterocyclic sulphonamides have achieved great
commercial significance as their applications in bacterial chemotherapy is well
known. Considerable interest has been shown in the chemistry of sulphonamides
due to their use as antibacterial, anticancer, antimalarial, antifungal, antiplasmodic,
anticonvulsant, herbicidal, pesticidal, antiinflammatory and analytical preparation.
SYNTHETIC ASPECT
T h e  s y n t h e s i s  o f  s u l p h o n a m i d e s  h a v e  b e e n  r e p o r t e d  i n  t h e
l i te ra ture162-164.
BIOLOGICAL IMPORTANCE
Considerable research has been undertaken to extend the activity and
reduce toxicity of sulpha drugs. Monogram and review165,166 surveying  various
aspects of sulpha drugs have been published. The specific biological activities
have been represented as under.
















(p) Aspartyl protease inhibitor194
Recently,  H. Peyman et al.,195 have reported aryl sulphonamides (31) as
vitronectin receptor antagonists.
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Y. Isao et al.,197 have synthesized pyrimidinyl sulphonamides (33) as
endothelin receptor antagonists.
F. Walter et al.,194 have demonstrated pyrimidinyl sulphonamide (34) as
antagonists agent.
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on sulphonamides for their various method of synthesis and
different pharmacological activities, synthesis of pyrimidinyl sulphonamides have
been undertaken which can be summarized as under.
SECTION - I : P R E PA R AT I O N  A N D  B I O L O G I C A L  E VA L U AT I O N  O F
                        2-MERCAPTO-4-(P-ACETAMIDOPHENYL SULPHONYLAMINO)-
    5-CARBOXMIDO-6-ARYL PYRIMIDINES.
SECTION - II : PREPARATION AND BIOLOGICAL EVALUATION OF 2-
                        MERCAPTO-4-(P -AMINOPHENYL SULPHONYLAMINO)-
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-
(P-ACETAMIDOPHENYL SULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYL
PYRIMIDINES
Keeping in view the interesting properties160-164and pharmacological
activities165-198 sulphonamides, it has been revealed that sulphonamides are
valuable drugs for various diseases and for viral diseases. These observation
led us to synthesis of  some novel  2-mercapto-4-(p -acetamidophenyl
sulphonylamino)-5-carboxamido-6-aryl pyrimidines (Xa-j) by condensation of
2-mercapto-4-amino-5-carboxamido-6-aryl pyrimidines with p-acetamidophenyl
sulphonylchloride.
The constitution of the products (Xa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (Xa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
were compared with standard drugs.
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Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.
          Observed       Reported
IR SPECTRAL STUDY OF 2-MERCAPTO-4-(p -ACETAMIDOPHENYL

















































 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.




 S=O str. (asym)
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   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3+TFA ; Instrument : BRUKER Spectrometer
    (300 MHz)
 1.               2.353            3H                            singlet                -NHCOCH3
 2.               6.895-6.923                  2H                            doublet               Ar-Hd,d’ (J=8.62)
 3.               7.071-7.098                  2H                            doublet               Ar-Ha,a’ (J=8.18)
 4.               7.152-7.180                  2H                            doublet               Ar-Hb,b’ (J=8.26)
 5.               7.718-7.747                  2H                            doublet               Ar-Hc,c’ (J=8.61)
 6.               8.354                             1H                            singlet                 -NH
PMR SPECTRAL STUDY OF 2-MERCAPTO-4-(p -ACETAMIDOPHENYL
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-(p-
ACETAMIDOPHENYL SULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYL
PYRIMIDINES
(A) Preparation of 2-Mercapto-4-amino-5-cyano-6-(p-chlorophenyl)-
          1,6-dihydro pyrimidine (1e).
For preparation refer Part-I, Section-II (A), Page No. 47.
(B) Preparation of 2-Mercapto-4-amino-5-carboxamido-6-(p-chloro
          phenyl) pyrimidine (3e).
2 - Me r c a p t o - 4 - a m i n o - 5 - c y a n o - 6 - ( p - c h l o r o p h e n y l ) - 1 , 6 - dihydro
pyrimidine (2.65 gm, 0.01 M) was dissolved in concentrated sulphuric acid (20ml)
below 5 oC and kept for 48 hrs. at room temperature. The content was poured
into ice cold water and filtered. The product was isolated and crystallized
from ethanol. Yield : 51%; M.P. : 147°C, Rf : 0.54, (Required : C, 47.06%; H,
3.21%; N, 19.96% for C11H9N4OSCl, Found : C, 47.02%; H, 3.16%; N, 19.89%).
.
Similarly, other compounds (3a-j) were synthesized. The physical data
are recorded in Table No. 12.
(C) Preparat ion of  2-Mercapto-4- (p -acetamidophenyl  sulphonyl
          amino)-5-carboxamido-6-(p-chlorophenyl) pyrimidine (Xe).
A mixture of 2-mercapto-4-amino-5-carboxamido-6-(p-chlorophenyl)
pyr imidine (2.81gm, 0.01M)  and  p-acetamidophenyl sulphonylchlor ide
(2.33 gm, 0.01M) in pyridine (15 ml) was heated under reflux condition for five
hrs. The content was poured into crushed ice. Fil tered the product and
recrystallized from ethanol. Yield : 59%, M.P. : 185°C, Rf : 0.64, (Required : C,
47.75%; H, 3.35%; N, 14.66% for C19H16N5O4S2Cl, Found : C, 47.70%; H,
3.30 %; N, 14.60%).
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Similarly, other compounds (Xa-j) were synthesized. The physical data
are recorded in Table No. 13.
(D) Ant imicrobia l  act iv i ty  of  2 -Mercapto-4- (p -acetamidophenyl
          sulphonylamino)-5-carboxamido-6-aryl pyrimidines (Xa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
13a, 13b & 13c.
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l) Xa Xd Xg Xh
Xa Xd
Xa Xd Xg Xh
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4
-(P -AMINOPHENYL SULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYL
PYRIMIDINES
Look ing to  the b iodynamic  act iv i t ies165-198 and the o ther
properties160-164 of sulphonamides and in order to have highly potent
therapeut ic  agents ,  the synthes is  o f  2-mercapto-4- (p -aminopheny l
sulphonylamino)-5-carboxamido-6-aryl pyrimidines (XIa-j) have been undertaken
by the hydrolysis of 2-mercapto-4-(p-acetamidophenyl sulphonylamino)-5-
carboxamido-6-aryl pyrimidines with hydrochloric acid.
The constitution of the products (XIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (XIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds









    XIa-j                R=Aryl
Studies on pyrimidinyl sulphonamides 164
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.
          Observed       Reported
  IR  S P E C T R A L  S T U D Y  O F  2 - M E R C A P T O - 4 - ( p - A M I N O P H E N Y L
 S U L P H O N Y L A M I N O ) - 5 - C A R B O X A M I D O - 6 - ( p - M E T H O X Y P H E N Y L )

































 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)






 S=O str. (asym)























































Studies on pyrimidinyl sulphonamides 165
   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3+TFA ; Instrument : BRUKER Spectrometer
    (300 MHz)
 1.               3.925            3H        singlet            -OCH3
 2.               7.045-7.074                  2H        doublet               Ar-Hd,d’ (J=8.74)
 3.               7.397-7.426                  2H        doublet               Ar-Ha,a’ (J=8.59)
 4.               7.492-7.521                  2H                            doublet               Ar-Hc,c’ (J=8.75)
 5.               7.576-7.604                  2H                            doublet               Ar-Hb,b’ (J=8.48)
 6.               8.154                             1H                            singlet                -NH
  P M R  S P E C T R A L  S T U D Y  O F  2 - M E R C A P T O - 4 - ( p - A M I N O P H E N Y L
 S U L P H O N Y L A M I N O ) - 5 - C A R B O X A M I D O - 6 - ( p - M E T H O X Y P H E N Y L )
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-
(p -AMINOPHENYL SULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYL
PYRIMIDINES
(A) Preparation of 2-Mercapto-4-(p-acetamidophenyl sulphonylamino)-
-5-carboxamido-6-(p-methoxyphenyl) pyrimidine (Xh).
            For preparation refer Part-III, Section-I, Page No. 156.
(B) Preparation of 2-Mercapto-4-(p-aminophenyl sulphonylamino-5-
          carboxamido-6-(p-methoxyphenyl) pyrimidine (XIh).
A mixture of 2-mercapto-4-(p-acetamidophenyl sulphonylamino)-5-
carboxamido-6-(p-methoxyphenyl) pyrimidine (4.73gm, 0.01M) was dissolved in
concentrated hydrochloric acid (20ml) and heated under reflux condition for five
hrs. The content was poured into ice cold water and filtered. The product was
isolated and crystallized from ethanol. Yield : 58%, M.P. : 105°C, Rf : 0.64,
(Required : C, 52.90%; H, 3.94%; N, 16.24% for C19H17N5O4S2, Found : C,
52.85%; H, 3.90% ; N, 16.20%).
.
Similarly, other compounds (XIa-j) were synthesized. The physical data are
recorded in Table No. 14.
(C) Antimicrobial activity of 2-Mercapto-4-(p-aminophenyl sulphonyl
          amino)-5-carboxamido-6-aryl pyrimidines (XIa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
14a, 14b & 14c.
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5 - - - - - - - - - -
10 - - - - - - - - - -
25 11 12 10 10 12 11 10 11 10 12
50 12 12 10 11 12 11 10 12 10 12
10
0
13 13 12 13 13 13 12 12 12 12
25
0
13 14 12 13 14 13 13 13 13 14
50
0
14 14 13 14 14 14 14 14 13 14
5 - - - - - - - - - -
10 - - - - - - - - - -
25 12 14 11 12 13 12 11 13 12 13
50 13 14 12 12 13 13 11 13 12 14
10
0
13 15 14 14 14 15 13 14 14 14
25
0
14 16 14 14 15 15 13 15 15 15
50
0








































































































































































11 10 16 18
14 13 19 19
16 19 21 20
18 20 21 21
19 20 22 21
20 22 22 23
10 12 17 19
13 14 19 22
14 19 21 25
16 20 22 26
18 21 22 28
21 22 23 28





































































   
   
   
   
   
   
   


















































   
   
   
   
   
   
   
   
   
   


























































   
   
   
   

























































   
   
   
   
   
   









   
   
   
   
   
   
   
   
   
   
   
   
   
   
   











5 - - - - - - - - - -
10 - - - - - - - - - -
25 14 15 13 13 15 14 13 14 14 15
50 15 16 13 14 16 14 14 15 15 15
10
0
17 17 15 16 16 15 15 15 16 16
25
0
17 17 16 17 17 16 16 17 16 17
50
0
18 18 16 17 17 18 17 18 17 17
5 - - - - - - - - - -
10 - - - - - - - - - -
25 15 16 15 15 16 15 14 16 15 16
50 17 17 16 15 17 16 15 17 15 16
10
0
19 19 16 17 17 16 15 18 15 17
25
0
19 19 17 18 18 18 17 18 17 17
50
0








































































































































































14 14 20 22
15 17 23 25
16 23 28 26
19 23 28 27
20 23 28 29
22 23 28 29
12 12 16 19
18 16 19 22
19 19 22 23
20 22 22 24
21 23 23 25
23 23 23 28


















































































   
   
   
   
   
   
   


















































   
   
   
   
   
   
   
   
   
   























































   
   
   
   

























































   
   
   
   
   












   
   
   
   
   
   
   
   
   
   
   
   
   
   










5 - - - - - - - - - -
10 - - - - - - - - - -
25 17 18 16 17 18 17 17 18 17 18
50 18 18 17 18 18 18 17 18 18 18
10
0
20 20 18 19 19 19 19 19 19 19
25
0
21 20 19 20 20 20 20 20 20 20
50
0
22 21 20 20 21 21 20 20 21 20
5 - - - - - - - - - -
10 - - - - - - - - - -
25 18 19 18 19 19 19 18 19 18 19
50 19 19 18 19 20 19 19 19 19 19
10
0
21 20 20 21 20 20 20 21 20 21
25
0
22 22 20 22 21 22 22 21 22 21
50
0










































































































































































































































   
   
   
   
   
   
   


















































   
   
   
   
   
   
   
   
   
   













Studies on pyrimidinyl sulphonamides 174
REFERENCES
160. Shepherd, R.G.; Sulphanilamides and other g-amino benzoic acid antagonists in
          medicinal chemistry, Vol. 1, edited by A. Burger (Wiley Interscience Toronto), p. 255
          (1949).
161. Krupp M.A. and Chalton M.J.; Current medicinal diagnosis and treatment (1980).
162. Willms, Lothar; (Hoechst A.-G.) Ger. Offen. DE 3, 330, 603 (Cl. C07D239/47), 21Mar
          1985, Appl. 25 Aug 1983; 17 pp, Chem. Abstr., 103, 54094x (1985).
163. N. Alois, C. Jindrich, B. Jana, K. Jiri, H. Vladislava; Czech. CS 254, 541 (Cl. C07D239/
49), 15 sep 1988, Appl. 86/3,198, 4 May 1986; 3pp, Chem. Abstr., 111, 23530x (1989).
164. M. Drewes, R.F. Gesing, J.R. Jansen, K. Mueller, H. Riebel, M. Dollinger, H. Santel;
(Bayer A.-G., Germany) Ger.Offen. DE 19, 504, 281(Cl. C07D239/52), 14Aug 1996, Appl.
19, 504, 281, 9 Feb 1995, 9pp, Chem. Abstr., 125, 195684f (1996).
165. F.L. Rose; Chem. Ind. (London), 21, 658-65 (1964); Chem. Abstr., 61, 2901b (1964).
166. R.S. Mc Cutcheon;  Pharm. Index., 7, 4A, 4-8 (1984).
167. P.O. Wester; Acta Med. Scand., 196(6),  489-94 (1974); Chem. Abstr., 82,  93324g
          (1975).
168. Feit P. Worner, O.B.T. Neilsen and H. Bruun; Brit., 1, 523, 631 (1978); Chem. Abstr.,
91, 56629h (1979).
169. Cribb A.E.,  Lee Bel le L. ;  (Merck Research Laborator ies) West Paint  P.A.,  USA,
Advance drug react  Toxicol .  Rev.  1996,  US  Cl .  9-50 (Eng),  Chem. Abstr. ,  126,
220193a (1997).
170. E. Selvaag,  Thune P.; Chem. Abstr., 128, 347c (1998).
171. V. Hagen, E. Morgenstern and E. Georges; Pharmazie, 35(3), 183-5 (1980); Chem. Abstr.,
93, 106817g (1980).
172. J.J. Howbert, A.C. Thomas, F.K. Kenneth and V.T. Eddie; J. Med. Chem., 33(9), 2393-
407 (1990); Chem. Abstr., 113, 114771j (1990).
173. Hiroshi Yoshino, Norihiri Ueda, Nil Jima, Jan, Toru, Kotake, Yoshimalsa, Kentaro,
Tsukahara, Naoko, Watanabe, Tatsuo Haneda; PCT Int. Appl. WO 95, 03, 279 (1995);
Chem. Abstr., 122, 314588c (1995).
174. Tobler Hans; PCT Int. Appl. WO 93, 16, 079 (1993); Chem. Abstr.,120, 54559d (1994).
175. A. Go, S. Kudo, J. Jakashashi and R. Higare; Jpn. Kokai Tokkyo Koho Jp 06, 172, 323
(1994); Chem. Abstr.,122, 1332079 (1995).
176. Abe Takaaki, Akiyoshi Yuji et al.; Eur. Pat. App. Ep.  567, 014, 27 Oct. (1993); Chem.
Abstr., 121, 83357n (1994).
177. K. Henry Sobolewski and Dionizy Skwafski; nn. Acta Pol. Pharm. 46(3), 232-6 (1989);
Chem. Abstr., 114, 6421 (1991).
178. K. Joachim Seydel, Helmut Pieper and Albrecht Jung; Ger. Offen. DE. 3, 919, 214;
Studies on pyrimidinyl sulphonamides 175
Chem. Abstr., 114, 185536t (1991).
179. Yoshio Katahashi, Toyohik Okume, Akihiko Yanagi, Ikuro Honder and Hashisho Honda;
Jpn. Kokai Tokkyo Koho Jp 02, 286, 674; Chem. Abstr., 114, 164225 (1991).
180. K.H. Patel and K.R. Desai; Proc. Nat. Acad. Sci., India, Sect. A 60(1), 7 (1990); Chem.
Abstr., 114, 164164E (1991).
181. K.H. Sikotra, D.N. Nagar, V.H. Shah; J. Inst. Chemist (India); Vol.73, Part-3, pg.111
(2001); Chem. Abstr., 136, 401723a (2002).
182. J.M. Parmar, J.J. Modha, R.C. Khunt, A.R. Parikh; J. Inst. Chemist (India); Vol.73,
Part-3, pg.114 (2001); Chem. Abstr., 137, 63221r (2002).
183. J.J. Modha, N.J. Dutta, J.M. Parmar,  A.R. Parikh; J. Inst. Chemist (India); Vol.73,
Part-6, pg.206 (2001).
184. J.  Bartrol i ,  M. Anquita,  J.  Bel loe, E. Carcel lor  and C. Atmanza; US ,  5,  360, 813
          (1994); Chem. Abstr.,122, 4984g (1995).
185. K. Rama Rao, Y.V.D. Nageswar, T.N. Srinivasan and P.B. Sattur; Indian J. Chem.,
          29B, 1041 (1990).
186. J.C. Henquin; Diabotologia 60(1), 904-12 (1992); Chem. Abstr.,118, 87p (1993).
187. L. Anderson, M. Kangasaho and H. Nikander; PCT Int. Appl. WO 88, 07, 991 (1988);
Chem. Abstr., 110, 135085s (1989).
188. Yoshikawa Yashinavi, Saito Hidesi and Oochi Yutake; Jpn. Kokai Tokkyo Jp 04, 174,
782 (1992); Chem. Abstr., 118, 38917 (1993).
189. W.I. Yasaka and P. Braz; PIBR 9201, 786 (1993); Chem. Abstr., 122, 25918f (1995).
190. M.L. Vazquez and Co-workers ; Pat. Int. Appl. WO 94, 04, 493 (1994); Chem. Abstr.,
122, 55727k (1995).
191. M.I. Reider, R. Krause, I.R. Bird and G.A. Debakan; J. Acquired Immune Defic, Syndr.
Hum. Retroviro. 8(2), 134 (1995); Chem. Abstr., 122, 230194n (1995).
192. William Loh, Lucille A. Cosby and Alan C. Sartorelli; J. Med. Chem., 23, 630 (1980).
193. M.A. Kaldrikyan, V.A. Geboyan and A.R. Avoyani; Arm. Khim. Zh., 33(3), 242-6 (1980);
Chem. Abstr., 93, 114216q (1980).
194. Tung Roger, D. Mureko Mark A. Bhiselti, Govinda R.; 87 pp Cont. in of U.S. Ser. No.
          941-982 abandones (Eng); Chem. Abstr., 128, 144117m (1998).
195. Peyman Helmut and co-workers; PCT Int. Appl. WO 99, 37, 621 (1999); Chem. Abstr.,
128, 489, 23 (1998).
196. Breu, Volker; US Appl. 676, 313 (1996); Chem. Abstr., 130, 13993d (1999).
197. Y.I. Isao, H. Hironari, K. Jun-Ichi , W. Susumu, T. Ryuji, S. Katsumi; Chemical &
pharmaceutical Bulletin 2001, 49 (12), 1593-1603 (Eng), pharmaceutical society of
          Japan, Chem. Abstr., 136, 263139m (2002).
198. F. Walter; W. Thomas; B. Martin; B. Christoph; C. Martine; Actelion pharmaceutical









Pyrazolo[3,4-d]pyrimidine (35) is a fused heterocyclic compound in which
pyrimidine with its d-position is fused at 3,4-position of pyrazole ring system.
R. Justoni et al.,199 have synthesized 1H-pyrazolo[3,4-d]pyrimidine 4(5H)-
ones-6-methyl-1,3-diphenyl in 1938. Pyrazolo[3,4-d]pyrimidine ring system is
isomeric with the purine (36) ring system and therefore, is of interest as a model
for biologically active compounds. Pyrazolo[3,4-d]pyrimidine is also known as
allopurine.
There are other two possible isomers of pyrazolo[3,4-d]pyrimidines, which


















             (36)









                  (37)
 Pyrazolo[1,5-a]pyrimidine




Extensive studies have been made in the field of synthesis of pyrazolo
[3,4-d]pyrimidines. Various methods for the preparation of pyrazolo[3,4-d]
pyrimidines have been described as under:
(a) By the condensation of 5-amino-4-cyano-pyrazole with 5-nitro-2-furonitrile
led to formation of 4-amino-6-(5’-nitro-2’-furyl)-1H-pyrazolo [3,4-d]
pyrimidines200.
(b) By the cyclocondensat ion of  4,6-dichloro-5-formylpyr imidine wi th
hydrazine hydrate led to formation of 1H-pyrazolo[3,4-d]pyrimidines201.
(c) 1,3-dimethyl-6-hydrazino uracil is fused at 150oC with dimethyl formamide
dimethylacetal (DMFDMA) led to formation of 2-alkyl-5,7-dimethyl pyrazolo
[3,4-d]pyrimidine-4,6(5H, 7H)-diones202.
(d) By the fusion of 5-arylazo-6-arylidene-hydrazino-1,3-dimethyl uracils at
200oC led to formation of 2-benzyl-5,7-dimethyl-3-phenyl pyrazolo[3,4-d]
pyrimidines-4,6(5H,7H)-diones203.
(e) By the cyclocondensation of 5-amino-4-cyano pyrazole with guanidine
carbonate led to formation of 4,6-diamino pyrazolo[3,4-d]pyrimidines204.
(f) By the cyclocondensation of arylidene derivative of 1,3-diphenyl uracil with
hydrazine hydrate led to the formation of pyrazolo[3,4-d]pyrimidines205.
(g) By the cyclocondensation of 4-carboxamido-5-amino-1,2,3-tr ihydro
pyrazo le  w i th  fo rmamide led  to  the  fo rmat ion  o f  pyrazo lo [3 ,4-d ]
pyrimidines206.
(h) By the cyclocondensation of 3,4-dicyano-5-amino-1-N-substitied pyrazole
with trichloro acetonitrile led to formation of pyrazolo[3,4-d] pyrimidines207.
(i) By the cyclocondensation of 3-aryl-2-arylamino-5-cyano-6-methyl-sulphonyl
pyrimidine-4-one with hydrazine hydrate  led to formation of pyrazolo
[3,4-d]pyrimidines208.
(j) By the cyclization of 2-chloro-6-methoxy quinolin-3-carboxaldehyde and
3-methyl-1-N-phenyl-5-pyrazolone with thiourea led to formation of
          pyrazolo[3,4-d]pyrimidines209.
178Studies on pyrazolo[3,4-d]pyrimidines
Pyrazo lo [3 ,4-d]pyr imid ines were found to  possess remarkable
fungicidal 210 (39), pesticidal 211,212 (40) and herbicidal 213 (41) activities.
BIOLOGICAL IMPORTANCE
Considerable research has been undertaken to extend the activity and
reduce toxicity of Pyrazolo[3,4-d]pyrimidine. The specific biological activities have






(f) Analgesic, antipyretic, antiinflammatory223-226
(g) Antimycotic agent227









R                  (39)
         R=ph/4-CI-C6H4































F. Robert et al.,248 have conducted the studies of pyrazolo[3,4-d]pyrimidine
as a chemotherapeutic agent against neurospora. The family of 4-amino
pyrazolo[3,4-d]pyrimidines linked at 3 and 1 position by pyridoxine and
pyridoxamine which are involved in a thiamine metabolism and which are linked
by series of related compounds adenine, thiamine, caffeine and some vitamins
can exhibit neurospora growth. E. Harward et al.,249 tested 4-amino pyrazolo
[3,4-d]pyrimidines and its methyl derivative as significant growth inhibitor of
adrenocarcinoma 755 in mice. Machon et al.,250 have  synthesized pyrazolo
[3,4-d]pyrimidines (42) which possess carcinostatic activity at 50 mg/kg gave 71








        (42)
Dobrynine et al.,251 have tested 3,4-disubstituted-6-(methylmercapto)
pyrazolo[3,4-d]pyrimidines (43) for cytotoxic activity on a human overiancarcinoma
cell and antiviral activity against Herpes and Pox infection in chicken fibroblasts.
180Studies on pyrazolo[3,4-d]pyrimidines
Fusishita et al.,252 have synthesized pyrazolo[3,4-d]pyrimidines (44) as
angiotensin (II) antagonists.
R. P. Tripathi et al.,253 have synthesized 2',2'-anhydro nucleosides of
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181Studies on pyrazolo[3,4-d]pyrimidines
M.L. Taha et al.,254 have synthesized 1-(2-hydroxy ethoxymethyl)
pyrazolo[3,4-d]pyrimidines (46) as antiHIV agents.
Oocta et al., 255 have prepared 1H-pyrazolo[]3,4-d]pyrimidines (47) as
potent antihypertensive and cardiovascular agent.
Y. Xia et al.,256 have synthesized polycyclic pyrazolo[3,4-d]pyrimidines (48)
and evaluated as PDE-1, PDE-5, CGMF-phosphodiesterase inhibitor. This
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182Studies on pyrazolo[3,4-d]pyrimidines
A. Straub et al.,257 have synthesized pyrazolo[3,4-d]pyrimidines (49) with
better cardiovascular agents.
Recently,  A.S. Bell et al.,258 have prepared pyrazolo[3,4-d]pyrimidines
(50) are useful for treatment of memory enhancement, hypertension, congestive
heart failure and female sexual dysfunction.
M. Friedman et al.,259 have prepared 3-(azo hetero)aryl-1H- pyrazolo
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183Studies on pyrazolo[3,4-d]pyrimidines
J. Markwalder et al.,260 have synthesized 6-substitited pyrazolo[3,4-d]
pyrimidin-4-ones (52) useful as cyclin dependent Kinase (cdk) inhibitors for
treating cancer and proliferative diseases.
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on pyrazolo[3,4-d]pyrimidines for their various methods of
synthesis and different pharmacological activities, synthesis of pyrazolo
[3,4-d]pyrimidines have been undertaken which can be summarized in the
following section as under.
SECTION - 1 :  PREPARATION AND BIOLOGICAL EVALUATION OF 3-AMINO-
                          4-ARYL-4,5-DIHYDRO-6-HYDRZINO-1H-PYRAZOLO[3,4-d]













           (52)
184Studies on pyrazolo[3,4-d]pyrimidines
SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 3-AMINO-4-ARYL-4,5-
DIHYDRO-6-HYDRAZINO-1H-PYRAZOLO[3,4-d]PYRIMIDINES
In view of various biodynamic activities214-260, other  properties199-213
of pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic
agents, the synthesis of 3-amino-4-aryl-4,5-dihydro-6-hydrazino-1H-pyrazolo
[3,4-d]pyrimidines (XIIa-j) have been undertaken by the condensation of 2-
mercaptomethyl-4-amino-5-cyano-6-aryl-1,6-dihydro pyrimidines with hydrazine
hydrate.
The constitution of the products (XIIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (XIIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds










XIIa-j                 R=Aryl
185Studies on pyrazolo[3,4-d]pyrimidines
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.




































 C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)























































   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3 ; Instrument : BRUKER Spectrometer
    (300 MHz)
 1.               3.853                              3H                           singlet                -OCH3
 2.               6.932-6.980                   2H                           doublet              Ar-Ha,a’ (J=8.76)
 3.               7.757-7.804                   2H                           doublet              Ar-Hb,b’ (J=8.79)
 4.               8.612                              1H                           singlet                Ar-Hc



























































































































































































































































































































PREPARATION AND BIOLOGICAL EVALUATION OF 3-AMINO-4-ARYL-4,5-
DIHYDRO-6-HYDRAZINO-1H-PYRAZOLO[3,4-d]PYRIMIDINES
(A) Preparation of 2-Mercaptomethyl-4-amino-5-cyano-6-(p-methoxy
          phenyl)-1,6-dihydro pyrimidine (IIh).
For preparation refer Part-I, Section-II, Page No. 47.
(B) Preparat ion of  3-Amino-4-(p -methoxyphenyl) -4 ,5-dihydro-6-
hydrazino-1H-pyrazolo[3,4-d]pyrimidine (XIIh).
A mixture of 2-mercaptomethyl-4-amino-5-cyano-6-(p-methoxyphenyl)-1,6-
dihydro pyrimidine (2.74 gm, 0.01 M) and hydrazine hydrate (1.0 ml, 0.02M) in
ethanol (30 ml) was heated under reflux condition for five hrs. The content was
poured into ice cold water and filtered. The product was isolated and crystallized
from ethanol. Yield : 62%, M.P. : 143°C, Rf : 0.63, (Required : C, 52.75%; H,
5.49%; N, 35.90% for C12H15N7O, Found : C, 52.70%; H, 5.45%; N, 35.85%).
Similarly, other compounds (XIIa-j) were synthesized. The physical data are
recorded in Table No. 15.
(C) Antimicrobial activity of 3-Amino-4-(p-methoxyphenyl)-4,5-dihydro
          -6-hydrazino-1H-pyrazolo[3,4-d]pyrimidines (XIIa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
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5 - - - - - - - - - -
10 - - - - - - - - - -
25 12 10 11 12 11 10 12 11 12 10
50 12 11 11 12 11 10 12 11 12 10
10
0
13 12 12 14 13 12 12 13 12 12
25
0
13 13 14 14 13 12 14 13 13 13
50
0
14 14 14 14 14 13 14 14 13 14
5 - - - - - - - - - -
10 - - - - - - - - - -
25 13 12 13 14 12 12 14 12 13 12
50 14 12 13 14 13 12 14 12 13 12
10
0
16 14 14 15 15 14 15 14 14 14
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50
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11 10 16 18
14 13 19 19
16 19 21 20
18 20 21 21
19 20 22 21
20 22 22 23
10 12 17 19
13 14 19 22
14 19 21 25
16 20 22 26
18 21 22 28
21 22 23 28
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10 - - - - - - - - - -
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10
0
17 14 16 17 16 15 16 15 16 15
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0
17 16 18 17 17 17 17 16 18 17
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0
18 17 18 17 18 18 18 17 18 17
5 - - - - - - - - - -
10 - - - - - - - - - -
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18 16 17 17 17 17 18 16 17 17
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0
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50
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16 23 28 26
19 23 28 27
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22 23 28 29
12 12 16 19
18 16 19 22
19 19 22 23
20 22 22 24
21 23 23 25
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0
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0
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[B]       STUDIES ON PYRIDO[2,3-d : 6,5-d']DIPYRIMIDINES
INTRODUCTION
Pyrido[2,3-d : 6,5-d']dipyrimidine (53) is a fused heterocyclic compound in
which two pyrimidines with their d-position are fused at 2,3 and 6,5 positions of
pyridine ring system.
K.R. Roland et al.,261 have synthesized 4 and 2,4-disubstituted pyrido
[2,3-d]pyrimidines in 1959. There are other three possible isomers of pyrido
pyrimidines which are fused at different position and four isomers represented
under.
SYNTHETIC ASPECTS
Extensive studies have been made in the field of synthesis of pyrido
[2,3-d]pyrimidines, Various methods have been reported in the literature which


















                        (54)
     Pyrido[3,2-d]pyrimidine
                        (56)
     Pyrido[3,4-d]pyrimidine
                        (55)
     Pyrido[4,3-d]pyrimidine
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(a) By the  cyc locondensat ion  o f  pyr imid ine carboxa ldehyde wi th  N-
substituted 2-cyano acetamide262.
(b) By the cyclocondensation of 4-amino pyrimidine with ethoxydiethyl
methylene malonate led to the formation of 5-oxo-2-(4/3-pyrimidinyl)
 pyrido[2,3-d]pyrimidine-6-carboxyllic acid263.
(c) By the reaction of 2-(m-nitroaniline)-3-carbethoxy pyridine with N-carb
ethoxyaminomethane led to formation of pyridopyrimidinediones264.
(d) By the cyclocondensation of 2-pyrido thione derivatives with benzoyliso
          th iocyanate  or  malononi t r i le  led to  the format ion o f  pyr ido[2 ,3-d ]
          pyrimidine265.
(e) By the cyclocondensation of 2-amino-pyridine-3-carboxyllic acid with
urea led to formation of 2,4-dioxo pyrido[2,3-d]pyrimidines266.
(f) By the hydrolysis of 2-amino-3-cyano-4,6-disubstituted pyridines to
2-amino-3-carboxamido-4,6-disubstituted pyridines fol lowed by the
treatment with aryl isocyanate led to the formation of 3,5,7-tri substituted
pyrido[2,3-d]pyrimidines267.
(g) By the cyclization of 3-cyano-1,4-dimethyl-5-ureidomethylene-1H,5H-
pyridin-2,6-dione in presence of phosphorous pentoxide led to formation
of pyrido[2,3-d]pyrimidines268.
(h) By the condensation of 4-amino-2-methoxypyrimidine-5-carboxaldehyde
            with diethyl malonate led to the formation of pyrido[2,3-d]pyrimidines269.
(i) By the cyclocondensation of 6-amino-2-methoxy-3,4-dihydro-4-pyrimidine
          with arylidene derivatives of malononitrile led to the formation of pyrido
          [2,3-d]pyrimidines270.
(j) By the reaction of 5-formyl-4-amino-2-oxopyrimidine with ethylcyano
acetate led to formation of pyrido[2,3-d]pyrimidines271.
(k)      By the cyclocondensation reaction of aromatic aldehyde with 2 moles of
thiobarbituric acid and aromatic amines272.
(l)       By the cyclocondensation reaction of 6-[(dimethylamino)methylene]-amino-
          1,3-dimethyluracil and Benzalacetone led to formation of pyrido[2,3-d]
pyrimidines273.
(m)     By the reaction of 1,3-diaryl-2-thiobarbitur icacid with thiophene-2-
          carbaldehyde and aniline led to formation of pyrido[2,3-d]pyrimidines274.
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Pyrido[2,3-d]pyrimidine have been found to possess remarkable
insecticidal275 (57) and herbicidal276 (58) activities.
Pyrido[2,3-d]pyrimidine derivatives from a class of fused heterocyclic
compound which have interesting pharmacological and biological activities,
particularly the oxo and amino derivatives of pyrido[2,3-d]pyrimidines standout
for their antitumor277 and antiviral278 activities.
BILOGICAL IMPORTANCE
The extensive use of pyrido[2,3-d : 6,5-d']dipyrimidines in medicine is due
to its vast biological activities, which are summarized as below.
(a) Antibacterial279-284
(b)      Anticancer285,286
(c)      Diuretic287-291
(d) Anticonvulsant292-294
(e)      Antitumor295-301
(f) Antiallergic agent302,303
(g) Antiphlogistic304
(h)      CNS depressant305-311
(i)       Antitussive312
(j)       Coronary vasodilator313
(k)      Antihypertensive314-316
(l)       Antiarrythmic agent317
















R4                        (57)
     R=4-CI-C6H4 / 4-CH3-C6H4
                        (58)
     R1=sub. phenyl, R2=H,
      R3=H, R4=H / Alkyl
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(n) Antispasmodic319
(o)      Cardiovascular320
(p)      Antiepileptic321,322
(q)      Antiprotoxoal323
(r)       Anxiolyticagent324,325
(s)      Antiasthamintics326
(t) Antitubercular327
(u) AntiHIV328,329
R.F. Meyer et al.,330 have synthesized 6-aryl-2,7-bis[(trialkylsilyl)amino]
pyrido[2,3-d]pyrimidines (59) and were administered orally to fasting rats at
2 mg/kg and 20 mg/kg and was effective as diuretic.
S. Minami et al.,331 have synthesized pyrido[2,3-d]pyrimidines (60) and
tested  for antibacterial ED50 i.p. in mice against pseudomonas aurigenous
6.3 gm and salmonella typhimurium 15.5 mg/kg and an i.v. LD50>500 mg.kg.
A. Santi l l i  et al. ,332 have synthesized 5,6,7,8-tetrahydro-5-oxo-pyrido
[2,3-d]pyrimidines-6-carbonitrile (61) and tested as central nervous system
depressants in mice at 12.7 to 40mg/kg i.p.














R     (60)








R.P. James et al.,333 have synthesized pyrido[2,3-d]pyrimidines (62) as
greater antifolate selectivity for antitumor over normal proliferative tissue.
T. Bear et al.,334 have synthesized pyrido[2,3-d]pyrimidines (63) as
potent antitumor agent. C.J. Blankyel et al.,335 have synthesized 6-aryl-pyrido
[2,3-d]pyrimidines (64) and found useful as inhibitors of protein tyrosine kinase























     (62)
     (63)
     (61)
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H. Sato et al.,336 have synthesized pyrido[2.3-d]pyrimidines (65) as
aldose reducatase inhibitors.
Y. Yonezawa  et al.,337 have synthesized pyrido[2,3-d]pyrimidines (66) as







     (64)
 R1, R2, NR3R4 = H / C1-8alkyl / C2-8alkyl;
















     (66)
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E.C. Tyloret al.,338 have synthesized glutamic acid 5,6,7,8-tetrahydro
pyrido[2,3-d]pyrimidines (67) as antineoplastic agent.
D.H. Boshelli et al.,339 have synthesized pyrido[2,3-d]pyrimidines (68),(69)
and found useful in the treatment of cell proliferatives disorders such as cancer
and restenosis.
J.B. Kramer et al.,340 have synthesized 2-(4-pyridyl)amino-6-dialkoxy-
phenyl-pyrido[2,3-d]pyrimidin-7-ones (70) as novel antiangiogenic agents and









     (67)
 R1=OH / NH2 ; R2=OH ; R3=H ;










     (68)
 R1=R2=H ; R3=H / alkyl ; R4=R5=H ;














     (70)
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H. Zhou et al.,341 have synthesized pyrido[2,3-d]pyrimidin-7-ones (71) as
useful for treating cell proliferative disorders, such as cancer, atherosclerosis and
restenosis.
In view to get potent therapeutic agents, the synthesis of pyrido[2,3-d : 6,5-d]
dipyrimidine derivatives have been undertaken which can be described as under.
SECTION - I :  PREPARATION AND BIOLOGICAL EVALUATION OF 1,2,3,4,
     6,7,8,9-OCTAHYDRO-10-ARYL-5-(o-CHLOROPHENYL)-
                          2 , 4 , 6 , 8 - T E T R A O X O - 5 H , 1 0 H - P Y R I D O [ 2 , 3 - d  :  6 , 5 - d ’ ]
                          DIPYRIMIDINES
SECTION - II : PREPARATION AND BIOLOGICAL EVALUATION OF 1,2,3,4,
     6,7,8,9-OCTAHYDRO-10-(p-METHYLPHENYL)-5- ARYL-2,8-
     DIMERCAPTO-4,6-DIOXO-5H,10H-PYRIDO[2,3-d : 6,5-d’]
     DIPYRIMIDINES
SECTION - III : PREPARATION AND BIOLOGICAL EVALUATION OF 1,2,3,4,
      6,7,8,9-OCTAHYDRO-10-ARYL-5-(m-NITROPHENYL)-2,8-
      DIMERCAPTO-4,6-DIOXO-5H,10H-PYRIDO[2,3-d : 6,5-d']
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207Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 1,2,3,4,6,7,8,9-
OCTAHYDRO-10-ARYL-5-(o-CHLOROPHENYL)-2,4,6,8-TETRAOXO-5H,10H-
PYRIDO[2,3-d : 6,5-d']DIPYRIMIDINES
In view of various biodynamic activities279-329,  other properties275,276,
literature survey330-341 and in order to have potent therapeutic agents,
synthesis of 1,2,3,4,6,7,8,9-octahydro-10-aryl-5-(o-chlorophenyl)-2,4,6,8-tetraoxo-
5H,10H-pyrido[2,3-d : 6,5-d']dipyrimidines (XIIIa-n) have been under taken by the
cyclocondensation of different aromatic amines with two moles of barbituric acid
and o-chlorobenzaldehyde in ethanol.
The const i tut ion of the products (XII Ia-n) have been del ineated by
elemental analyses, IR, PMR and Mass spectral data.
The products (XIIIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds













XIIIa-n                 R=Aryl
208Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.
















IR SPECTRAL STUDY OF 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 - O C TA H Y D R O - 1 0 - ( p -
METHOXYPHENYL)-5 - (o -CHLOROPHENYL) -2 ,4 ,6 ,8 -TETRAOXO-































 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)





























































209Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3+DMSOd6 ; Instrument : BRUKER
    Spectrometer  (300 MHz)
  1.         3.651            3H         singlet -OCH3
  2.         5.645            1H         singlet Ar-HC
  3.               6.630-6.668            2H         doublet Ar-Hb,b’
  4.               6.758-6.767            1H         doublet Ar-Hd
  5.         6.826-6.855            2H         doublet Ar-Ha,a’
  6.               7.049-7.104                  1H                            multiplet Ar-He
  7.         7.118-7.171            1H         multiplet Ar-Hf
  8.         7.236-7.311            1H         multiplet Ar-Hg
  9.         8.484                        1H         singlet -NH
  10        10.045            1H         singlet -NH
  11.        10.304                        1H         singlet -NH
PMR SPECTRAL STUDY OF 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 - O C TA H Y D R O - 1 0 - ( p -
METHOXYPHENYL)-5 - (o -CHLOROPHENYL) -2 ,4 ,6 ,8 -TETRAOXO-






























































































































































































































































































































213Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 1,2,3,4,6,7,8,9-
OCTAHYDRO-10-ARYL-5-(o-CHLOROPHENYL)-2,4,6,8-TETRAOXO-5H,10H-
PYRIDO[2,3-d : 6,5-d']DIPYRIMIDINES
(A) Preparation of 1,2,3,4,6,7,8,9-Octahydro-10-(p-methoxyphenyl)-5-
          (o-chlorophenyl)-2,4,6,8-tetra-oxo-5H,10H-pyrido[2,3-d : 6,5- d']
dipyrimidine (XIIIi).
A mixture of o-chlorobenzaldehyde (1.41 ml, 0.01 M), barbituric acid
(2.60 gm, 0.02 M) and p-anisidine (1.23 gm, 0.01 M) in ethanol (30 ml) was heated
under refluxed condition for six hrs. The content was poured into ice cold  water.
The separated solid was filtered and crystallized from DME:methanol (2:1). Yield
: 79%, M.P. : 196°C, Rf : 0.46, (Required : C, 56.71%; H, 3.44%; N, 15.04% for
C22H16N5O5Cl, Found : C, 56.65%; H, 3.40%;  N, 14.99%).
Similarly, other compounds (XIIIa-n) were synthesized. The physical data
are recorded in Table No. 16.
(B) Antimicrobial activity of 1,2,3,4,6,7,8,9-Octahydro-10-aryl-5-(o-chloro
          p h e n y l ) - 2 , 4 , 6 , 8 - t e t r a o x o - 5 H , 1 0 H - p y r i d o [ 2 , 3 - d  :  6 , 5 - d ' ]
dipyrimidines (XIIIa-n).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
16a, 16b & 16c.
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218Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 1,2,3,4,6,7,8,9-
OCTAHYDRO-10-(p-METHYLPHENYL)-5-ARYL-2,8-DIMERCAPTO-4,6-
DIOXO-5H,10H-PYRIDO[2,3-d : 6,5-d']DIPYRIMIDINES
In view of various biodynamic activities279-329,  other properties275,276,
literature survey330-341 and in order to have potent therapeutic agents,
synthesis of 1,2,3,4,6,7,8,9-octahydro-10-(p-methylphenyl)-5-aryl-2,8-dimercapto-
4,6-dioxo-5H,10H-pyrido[2,3-d : 6,5-d']dipyrimidines (XIVa-k) have been under
taken by the cyclocondensation of different aromatic aldehydes with two moles of
thiobarbituric acid and p-toluidine in ethanol.
The constitution of the products (XIVa-k) have been delineated by
elemental analyses, IR, PMR and Mass spectral data.
          The products (XIVa-k) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
were compared with standard drugs.













219Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.

















IR SPECTRAL STUDY OF 1,2,3,4, 6,7,8,9-OCTAHYDRO-10-(p-METHYL
PHENYL)-5-(m-NITROPHENYL)-2,8-DIMERCAPTO-4,6-DIOXO-5H,10H-
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220Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3+DMSOd6+TFA ; Instrument : BRUKER
    Spectrometer (300 MHz)
 1.         2.368            3H        singlet -CH3
 2.         6.032            1H        singlet Ar-HC
 3.                7.437-7.587            2H        doublet Ar-Hb,b’
 4.                7.769-7.892            2H        doublet Ar-Ha,a’
 5.         7.831            1H        singlet -NH
 6.                7.953-8.013                  1H                           triplet Ar-He
 7.         8.274-8.300            1H        double doublet Ar-Hf
 8.         8.480-8.507            1H        double doublet Ar-Hd
 9.         8.704                        1H        doublet Ar-Hg
PMR SPECTRAL STUDY OF 1,2,3,4, 6,7,8,9-OCTAHYDRO-10-(p-METHYL
PHENYL)-5-(m-NITROPHENYL)-2,8-DIMERCAPTO-4,6-DIOXO-5H,10H-







































































































































































































































































































































































































































224Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 1,2,3,4, 6,7,8,9-
OCTAHYDRO-10-(p-METHYLPHENYL)-5-ARYL-2,8-DIMERCAPTO-4,6-
DIOXO-5H,10H-PYRIDO[2,3-d : 6,5-d']DIPYRIMIDINES
(A) Preparation of 1,2,3,4,6,7,8,9-Octahydro-10-(p-methylphenyl)-5-(m-
nitrophenyl)-2,8-dimercapto-4,6-dioxo-5H,10H-pyrido [2,3-d : 6,5- d']
dipyrimidine (XIVg).
A mixture of m-nitrobenzaldehyde (1.51 gm, 0.01 M), thiobarbituric acid
(2.92 gm, 0.02 M) and p-toluidine (1.07gm, 0.01 M) in ethanol (30 ml) was heated
under refluxed condition for six hrs. The content was poured into ice cold water.
The separated solid was filtered and crystallized from DME:methanol (2:1).
Yield : 77%, M.P. : 180°C, Rf : 0.49, (Required : C, 53.66%; H, 3.25%; N, 17.07%;
for C22H16N6O4S2, Found : C, 53.62%; H, 3.21%; N, 17.02%).
Similarly, other compounds (XIVa-k) were synthesized. The physical data
are recorded in Table No. 17.
(B) Antimicrobial activity of 1,2,3,4,6,7,8,9-Octahydro-10-(p-methyl
phenyl)-5-aryl-2,8-dimercapto-4,6-dioxo-5H,10H-pyrido [2,3-d : 6,5-d']
dipyrimidines (XIVa-k).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
17a, 17b & 17c.
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229Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
SECTION - III
PREPARATION AND BIOLOGICAL EVALUATION OF 1,2,3,4,6,7,8,9-
OCTAHYDRO-10-ARYL-5-(m-NITROPHENYL)-2,8-DIMERCAPTO-4,6-DIOXO-
5H,10H-PYRIDO[2,3-d : 6,5-d']DIPYRIMIDINES
Due to wide range of pharmacodynamic activit ies279-329, recent
literature survey330-341, other properties275,276 and in view to have potent
therapeutic agents, the synthesis of 1,2,3,4,6,7,8,9-octahydro-10-ayrl-5-
(m-nitrophenyl)-2,8-dimercapto-4,6-dioxo-5H,10H-pyrido[2,3-d : 6,5-d']
dipyrimidines (XVa-n) have been under taken by the cyclocondensation of
d i f ferent  aromat ic  amines wi th two moles of  th iobarb i tur ic  ac id and
m-nitrobenzaldehyde in ethanol.
The constitution of the products (XVa-n) have been delineated by
elemental analyses, IR, PMR and Mass spectral data.
The products (XVa-n) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds













XVa-n                 R=Aryl
230Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type             Vibration Mode             Frequency in cm-1                   Ref.

















































 C-H i.p. def.
 C-H o.o.p. def.
 C=S str.
 C-O-C str. (asym.)




























































231Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
   Signal Signal Position   Relative No.        Multiplicity Inference
     No.      (δ ppm)     of Proton
    Internal Standard : TMS ; Solvent ; CDCl3 ; Instrument : BRUKER Spectrometer
    (300 MHz)
  1.          3.830            3H         singlet  -OCH3
  2.          5.955            1H         singlet  Ar-HC
  3.                6.963-7.017            2H         doublet  Ar-Hb,b’
  4.                7.296-7.348            2H         doublet  Ar-Ha,a’
  5.          7.485-7.588            2H         multiplet  Ar-He ; Ar-Hd
  6.                8.025                        1H                            doublet  Ar-Hg
  7.          8.088-8.115            1H         double doublet  Ar-Hf























































































































































































































































































































































































































235Studies on pyrido[2,3-d : 6,5-d’]dipyrimidines
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 1,2,3,4, 6,7,8,9-
OCTAHYDRO-10-ARYL-5-(m-NITROPHENYL)-2,8-DIMERCAPTO-4,6-DIOXO-
5H,10H-PYRIDO[2,3-d:6,5-d']DIPYRIMIDINES
(A) Preparation of 1,2,3,4,6,7,8,9-Octahydro-10-(p-methoxyphenyl)
-5 - (m -n i t rophenyl ) -2 ,8 -d imercapto-4 ,6 -d ioxo-5H,10H-pyr ido
          [2,3-d : 6,5- d']dipyrimidine (XVi).
A mixture of m-nitrobenzaldehyde (1.51 gm, 0.01 M), thiobarbituric acid
(2.92 gm, 0.02 M) and p-anisidine (1.23 gm, 0.01 M) in ethanol (30 ml) was heated
under refluxed condition for six hrs. The content was poured into ice cold water.
The separated solid was filtered and crystallized from DME:methanol (2:1). Yield
: 79%, M.P. : 219°C, Rf : 0.53, (Required : C, 53.66%; H, 3.25%; N, 16.54% for
C22H16N6O5S2, Found : C, 53.60%; H, 3.20%; N, 16.49%).
Similarly, other compounds (XVa-n) were synthesized. The physical data
are recorded in Table No. 18.
(B) Ant imicrobial  act iv i ty  of  1 ,2 ,3 ,4 ,6 ,7 ,8 ,9-Octahydro-10-aryl
-5- (m -ni trophenyl) -2 ,8-dimercapto-4,6-dioxo-5H,10H-pyrido
[2,3-d : 6,5- d']dipyrimidines (XVa-n).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
18a, 18b & 18c. .
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NOTES
1. All the temperatures are expressed in degree centigrade (0C).
2. All melting points are uncorrected and have been recorded by
open capillary method.
3. Room temperature wherever mentioned, normally corresponds
to 28-33 0C.
4. Silica gel-G was used for preparing the plates for TLC using
different solvent systems.
5. Infra red spectra were recorded on SHIMADZU-FTIR-8400
Spectrophotometer using KBr disc.
6. PMR Spectra were recorded on BRUKER Spectrophotometer
(300 MHz) using TMS as a internal standard and CDCI3, DMSOd6
and TFA as solvents.
7. FAB mass spectra were recorded on JEOL SX 102/DA-600-
Mass Spectrometer. The matrix peaks appear at m/z 136,137,
154,289,307 in the absence of any metal ions were not
shown for mass fragmentations.
